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Abstract

STUDIES ON RATIONALLY DESIGNED, ALLOSTERIC, COAGULATION
INHIBITORS
By Rio S. Boothello, BPharm.
A Dissertation submitted in partial fulfillment of the requirements for the degree of PhD in
Pharmaceutical Sciences at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Major Director: Dr. Umesh R. Desai
Professor, Department of Medicinal Chemistry
Heparin is a natural allosteric modulator, with numerous structural and conformational
variations leading to many reports of bleeding complications and variations in
anticoagulant effects. A flurry of research has been directed towards understanding this
puzzle. This work entails the utilization of three unique strategies to further our
understanding of this complex issue.
Traditional synthetic, biosynthetic and biophysical approaches have failed to
conquer the GAG-protein complexity. Computational analysis however could serve as a
powerful approach to decipher this dilemma. A dual filter algorithm was incorporated to
identify unique hexasaccharide sequences for HCII and AT. Our experimental studies
exhibit a good correlation with our computational findings in addition, to the discovery of

the first reported heparin based hexasaccharide sequence (HX1) as a potent
activator of HCII and AT.
In contrast to the enormity of GAG sequences, there appears to be a pattern where
rare sequences have been identified to modulate characteristic functions in proteins. Our
search led us to a biosynthetically rare GAG residue 2-O-sulfated glucuronic acid
(GlcAp2S). Our computational studies indicated elements of selective recognition with
coagulation enzymes propelling us towards synthesizing a polymer, HS2S2S enriched in
GlcAp2S and GlcNp2S saccharides. Our biological studies indicate its potential in
activating AT and HCII in addition to a previously unobserved inhibition of thrombin but
not FXa, which is corroborated by our computational studies. These studies therefore
showcase the importance of studying rare sequences to further our understanding of
differential recognition of proteins of the coagulation cascade.
An alternate anticoagulant strategy involves utilization of upstream enzymes like
FXIa. Consequently, we devised a rational strategy, which targets the differential
hydrophobic domain near the heparin binding sites of proteins through the design of
molecules termed as sulfated allosteric modulators. Our endeavor led to the discovery of a
library of quinazolin4-(3H)ones) dimers as selective inhibitors of FXIa. We recognized the
linker length and geometry to be an important element affecting potency and selectivity.
We therefore synthesized a library of 18 dimers using simple reaction schemes. Our
inhibition studies do highlight a 9-fold improvement in potency.

CHAPTER 1: INTRODUCTION
1.1. Allosterism
Allostery implies regulation at a distance.1 Largely associated with conformational and
functional transitions in the target protein, “Allosterism” is a term coined by Monod and
Jacob in a summary report “Cellular Regulatory Mechanism.”2 This phenomenon was
initially formulated to explain the lac repressor binding on inducer and operator DNA
sequences in addition to the effect observed on Escherichia coli dimeric threonine
deaminase by L-isoleucine.2,3 These eventually formed the basis of the Monod, Wyman
and Changeux model (the MWC model) of ‘concerted’ allosteric transition.2 In recent
years, newer views of allostery have been hypothesized that are further reshaping the
concept.4 By definition, allostery is a phenomenon that arises from the coupling of an
effector ligand binding at a remote (‘allos’) site (‘steros’) from the primary ligand site
which induces structural and/or dynamic change resulting in regulation of binding of the
primary ligand. The concept of allostery has expanded to numerous proteins that are
known to utilize this feature.4
1.1.1. Allostery+in+the+Regulation+of+Physiological+Processes+
Postulated as the most direct, rapid and efficient way to regulate protein
functioning, allostery has come a long way from first being observed as early as 1903 in
the sigmoidal binding curve of hemoglobin binding to O2, which initially baffled many,
but which remarkably led to the appearance of the concept of ‘Allosterism’ by Monod,
1

Wyman and Changeux.2 The concept of allostery has now expanded from multimeric
proteins to monomeric proteins and from native proteins to engineered proteins. The
functions this concept regulates now range from control of metabolic mechanisms to
signal-transduction pathways.3 Numerous allosteric proteins function in normal
physiology, but their roles in pathological states have now been uncovered.
Comprehensive databases like the ASD (Allosteric database) have been assembled and
these can be utilized to obtain information on allosteric proteins and modulators (Figure
1).5,6
1.1.2. Allosteric+sites+as+Drug+targets+
The$biological$prevalence$of$allostery$and$its$ability$to$have$a$huge$influence$
in$both$normal$and$diseased$states$warrants$its$applicability$as$a$therapeutic$target.$
Its$activation$or$inhibition$of$a$particular$protein,$unlike$standard$active$site$direct$
inhibitors,$makes$it$a$unique$tool$to$modulate$the$activity$of$a$protein.$
To$summarize,$allosteric$effectors$have$the$following$advantages$over$conventional$
direct$active$site$targets.$
1. In$ highly$ conserved$ protein$ families,$ the$ allosteric$ effectors$ are$ more$ specific$
since$ they$ do$ not$ bind$ to$ the$ active$ sites,$ which$ tend$ to$ be$ conserved$ in$ such$
cases.3$$
2. They$ have$ lower$ chances$ of$ side$ effects,$ which$ could$ make$ them$ very$ useful$ in$
combinatorial$strategies.1$
3. They$allow$for$modulation$of$protein$activity$rather$than$complete$elimination$of$
activity.4$
2

4. They$ generally$ work$ when$ the$ endogenous$ ligand$ is$ bound$ and$ could$ therefore$
be$used$in$cases$where$the$cell$is$not$functioning$normally.$
In$contrast$to$these$advantages,$allosteric$effectors$could$face$a$few$hurdles$
1. Unlike$ active$ site$ inhibitors,$ which$ interact$ with$ a$ known$ active$ site,$ allosteric$
sites$are$often$unknown$and$the$drug$modulatory$effects$are$difficult$to$predict.$
2. Similar$to$active$site$effectors,$allosteric$effectors$could$also$develop$resistance$
issues.$
3. There$ exists$ a$ higher$ divergence$ rate$ of$ allosteric$ sites$ in$ species$ homologs$
compared$to$that$seen$for$active$site$inhibitors.1$
4. Toxicity$ issues,$ generally$ due$ to$ high$ doses,$ which$ may$ arise$ from$ binding$ to$
additional$proteins,$or$to$formation$of$reactive$metabolites.$
Despite$these$challenges,$allosteric$effectors$have$displayed$tremendous$promise$in$
overcoming$the$problems$generally$observed$with$known$active$site$inhibitors$and$
are$therefore$being$pursued$with$increasing$vigor.$
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Figure 1. Statistics on the allosteric proteins and modulators from ASD. (A) Class
distribution of allosteric proteins. (B) Species distribution of allosteric proteins. (C)
Category distribution of allosteric modulators. (D) A history of the discovery of allosteric
modulators.6(Figure adapted from Reference 6)
1.2.

Allosteric Regulation of the Coagulation enzymes

Excessive loss of blood from injury and protection against microbial infiltration are easily
countered by the formation of a clot. This assures fine-tuning between blood flow and
cessation, maintained by a group of highly sophisticated systems which form part of the
hemostatic system. This essentially comprises the platelet dependent system, coagulation
system and the fibrinolytic system, also termed primary, secondary and the tertiary
hemostasis.7 The coagulation cascade is a highly intertwined system and forms a crucial
4

part of this system. The concerted and finely regulated action of a constellation of
proteins known as factors, the majority of which exhibit proteolytic enzymatic activity,
form the cascade. This cascade principally is comprised of enzymatic conversion of
zymogen to their activated form, which serves to activate a specific subsequent zymogen
and further propagates the cascade.
1.2.1 The Coagulation cascade
The coagulation cascade could be fundamentally divided into the three major pathways
1.Intrinsic pathway, 2. Extrinsic pathway, and 3. The Common pathway, which are
regulated by a group of physiological anticoagulant serine protease inhibitor (Serpins)
(Figure 2)8
Intrinsic pathway
In this pathway, all clotting factors are present in the blood and are activated when blood
comes in contact with activated platelets, collagen or other negatively charged surfaces as
in vascular endothelium damage, lipoproteins in hyperlipidemia, or bacteria in infections.
These initiate FXII attachment to the platelet membrane via the high molecular weight
kininogen (HMWK), which helps anchor it to further activate to FXIIa. A small amount
of FXIIa proteolytically cleaves FXI to FXIa. FXIa then converts FIX to FIXa, which
forms intrinsic tenase, a trimolecular complex. Tenase then converts FX to FXa, which
through the common pathway eventually culminates in the formation of thrombin and
eventually clot. In a laboratory setting this pathway can be monitored using the activated
partial thromboplastin time (APTT) assay.8-10

5

The Extrinsic pathway
Comparable to the intrinsic pathway, the extrinsic pathway similarly incorporates a
cascade of interactions. Initiated by an injury without direct contact with
nonphysiological surfaces, like endothelium damage, or by hypoxia resulting from
reduced blood flow, which drives the formation of a complex between TF on cell
surfaces and FVIIa located outside vascular system and hence the term extrinsic pathway.
The FVIIa/TF complex, analogous in function to the tenase complex, then converts FX to
its active form FXa (Figure 2). This is followed by the common pathway. In a laboratory
setting this pathway is monitored using the partial thromboplastin time (PT) assay.8,9
The Common pathway
Apparent by its name, the common pathway is the point of convergence of the intrinsic
and the extrinsic pathways. These converge with the formation of FXa, which in the
presence of FV, Ca+2 and phospholipids converts prothrombin to its active form thrombin
(TH). Thrombin primarily catalyzes the proteolysis of soluble fibrinogen to form fibrin
monomers. Fibrin monomers then self polymerize to form a clot that helps cease blood
flow. Thrombin is also known to activate FXIII to FXIIIa, which yields the covalent
cross-linking of the fibrin polymer to form stable fibrin mesh (Figure 2). In addition, to
these effects thrombin is known to catalyze its own formation from prothrombin. It can
catalyze the formation of the cofactors FVa and FVIIIa effecting an efficient
amplification of coagulation. Thrombin also provides positive feedback to the cascade by
activating upstream proteins like factor XI, factor VIII in the intrinsic pathway, and factor
6

V in the common pathway. This ensures the efficient functioning of the cascade.
Generally, deficiencies in any of the enzymes in the common pathway may result in
major bleeding disorders.7-10
Natural Regulators of Coagulation.
It is necessary to have a regulatory mechanism to limit clot formation as well as to
dissolve the clot when an injury has healed. This is facilitated by the presence of a variety
of activators and inhibitors. The tissue factor pathway inhibitor (TFPI), the activated
protein C (APC), antithrombin (AT) and heparin co-factor II (HCII) to name a few are
the known anticoagulants which help restore some control over the coagulation cascade.
The functions of each of these are summarized in the (Table 1). Of these, antithrombin, a
serine protease inhibitor (serpin) has garnered a lot of interest due to its accelerated
inhibition of thrombin, FXa and FIXa in the presence of heparin (H).
Antithrombin activation forms the mechanism of a number of heparin-based drugs on the
market. Another serpin gathering interest lately is HCII, which is known to inhibit
thrombin alone and could serve as a novel target. These serpins, could be targeted to
indirectly modulate the activity of the coagulation enzymes.10
Table 1. Natural regulators of coagulation.10,11
Name
TFPI
Activated Protein C
Antithrombin
Heparin cofactor II

Description
MW = 33,000 Da

Function
Inhibits the TF/FVIIa
complex

MW = 62,000 Da, vitamin k Cleaves FVa and FVIIa
dependent serine protease
MW= 58,000, Serpin
Inhibits thrombin, FXa
and FIXa
MW= 65,000, Serpin
Inhibits thrombin
7

A

B

Factor'XII'' Factor'XIIa''
Factor'XI''

Factor'XIa'
FVIIa/phospholipids/Ca+2''
Factor'VIIa'
@ssue'factor'
Ca2+'

Factor'IX'' Factor'IXa''
Factor'X'

Factor'Xa'

Factor'X'

FXa/FVa/Ca+2'

C

Prothrombin'
(Factor'II)'

Factor'VII'

Thrombin'
(factor'IIa)'

Antithrombin
ﬁbrinogen' Heparin co-factor II
ﬁbrin'

D

Figure 2. The coagulation system. (A) The intrinsic pathway, (B) the extrinsic pathway,
(C) The common pathway (D) natural regulators of coagulation.12
1.2.2. Examples of Allostery in the Coagulation Cascade
The extensive interconnectivity within the coagulation system implies the presence of
allostery. Allostery is indeed observed at different levels of coagulation, with many of
these widely studied in terms of structure, mechanism and effects on normal functioning
of these enzymes. A few examples of such systems are briefly described below to support
the fact that allostery is a crucial part of the coagulation cascade and unequivocally offers
new avenues in the development of drugs that could target these functions.
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Thrombin
Thrombin is a serine protease of prime importance to the coagulation cascade. A part of
its importance stems from its ability to interact with a multitude of substrates and
cofactors to perform numerous functions in the cascade. Recent studies have indicated
that the reason for this peculiar ability is the flexible structure of thrombin, which can be
modulated to produce a plethora of actions.13 Thrombin is known to possess three
allosteric sites in addition to the catalytic triad containing active site as shown in (Figure
3). These serve as platforms to orchestrate the coagulation cascade.10,13
Exosite I – is a highly positively charged site and is responsible to be essential in the
interaction with physiological substrates like PAR-1, GP1bα, and fibrinogen. This region
also forms the site of interaction of known drugs like hirudin, obtained from the leech
Hirudo medicinalis.
Exosite II – is another highly positive region decorated with numerous Arg and Lys
residues. Physiologically, it is a recognition site for FV, FVIII and GP1bα.13 This
allosteric heparin-binding site has been a hotspot for drug design efforts.
Na+ binding site – has been recognized as a vital site in regulating the activity of
thrombin. Studies have indicated the importance of this site as a switch to move thrombin
from the anticoagulant slow form to the procoagulant fast form. Na+ binding ensuring its
transition to the fast form.13
Allosteric sites have been observed in other serine proteases. A prime example includes
the heparin binding exosite II, which is also seen in FXa, FIXa and FXIa thus, affording
9

an allosteric handle to modulate the activity of these important serine proteases through
the design of newer anticoagulants.
Heparin
Chondroitin sulfate Exosite II
GP1bα

Hirugen (hirudin)
Exosite I GP1bα
PAR-1
Fibrinogen (fibrin)

Na+ binding site

Figure 3. The allosteric sites on thrombin.13 (Figure adapted from reference 13)
Antithrombin
Antithrombin is a serpin and a major physiological regulator of the coagulation cascade.
Antithrombin in its apoform is known to be a poor inhibitor of thrombin and other
enzymes. However, binding of a specific heparin pentasaccharide (H5) produces enough
conformational changes to accelerate its inhibition of FXa to ~300–fold.14 In contrast, it
accelerates thrombin inhibition through a unique bridging mechanism. This involves
binding of heparin at the pentasaccharide binding site of AT, while thrombin binds to
non-specific residues on the other end of the heparin chain and then walks through the
chain to be eventually inhibited by antithrombin, both of these mechanism are
schematically represented in (Figure 4).10,15 The allosteric nature of this interaction is
known to control antithrombin inhibition of a variety of enzymes, which therefore makes
10

this an interesting system. Specific modulation could hold the key utilizing this as a drug
target.10,15
Other examples of allostery in the coagulation cascade
Heparin is also known to allosterically modulate the activity of a number of enzymes in
the coagulation cascade, which include enzymes like FIIa, FVIIa, FXa and FIXa. Each of
these possesses a heparin binding exosite, which could be utilized in developing newer
anticoagulants. Serpins like HCII are also known to accelerate allosterically towards
thrombin inhibition without heparin. Studies to further understand the mechanism by
which these function have been undertaken and could be utilized to further realize the
potential that these possess.

Figure 4. The molecular mechanism of heparin activated antithrombin inhibition of
factor Xa, factor IXa, and thrombin. AT:H: antithrombin–heparin complex; RCL:
reactive center loop; fIIa: thrombin; FXa: factor Xa; FIXa: factor IXa; Gla: Gla domain
on fIXa/fXa; exosite on enzyme; HBS: heparin binding site.(Figure adapted from
Reference 10)10,15
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1.2.3. Implications for Design of Allosteric effectors
Allosteric interactions in the coagulation cascade could serve as a target for numerous
anticoagulant drug design strategies. Physiologically, allosterism in the coagulation
cascade is regulated by interaction between a larger protein and polymers. These
therefore incorporate a higher degree of uncertainty in terms of off-target effects,
heterogeneity and lack of bioavailability of these agents. Heparin is a prime example,
where the heterogeneity and the lack of structural understanding of its interaction has
been admirably overcome with the advent of variants of unfractionated heparin which
included low molecular weight heparins (LMWH) that eventually led to the identification
of heparin pentasaccharide DEFGH with a specific structure.16 This was not only
homogeneous but also selective in its interaction with AT, accelerating its FXa inhibition
alone. Further studies conducted toward understanding the individual saccharide units
essential for generating the acceleration indicated the presence of a trisaccharide
sequence, DEF that could produce the same degree of activity, with the disaccharide EF
considered to be providing stability to the active form of AT.14,17 Similarly, a number of
strategies have been utilized, which include the use of smaller oligosaccharides and
synthetic small molecules, and other glycosamino glycan (GAG)-coagulation protein
interactions can be similarly targeted.
Most anticoagulant drug design strategies typically aim to confer the following
advantages over the physiological effectors
1. The structure of these effectors can be well characterized and be easily synthesized in
larger quantities.
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2. Most of the allosteric sites can modulate the interaction with more than one enzyme;
hence specificity of interaction is an important feature (giving a predictable
anticoagulant effect).
3. No risk of thrombocytopenia.
4. A wide therapeutic window (eliminating the need for routine coagulation monitoring)
5. Bioavailability is another important feature that these need to possess.
6. Rapid onset and offset of action and a rapid offset too, thus allowing for easier
management of bleeds.
7. Presence of available antidotes could further improve the safety profile of these
agents.18,19
1.3. Direct and Indirect allosteric effectors
Risk of bleeding is a serious drawback of current anticoagulant therapy despite the
success it has enjoyed over a number of years. Observations with these agents indicate a
direct correlation between the intensity of anticoagulation and the severity of risk factors.
Efforts are therefore underway to discover and develop better and safer agents.15
Targeting enzymes in the coagulation cascade could be achieved by directly inhibiting
the enzyme of interest, in which case such effectors would be classified as direct
inhibitors. Other effectors that interact with physiologic regulators of coagulation and
accelerate inhibition of enzymes are known as indirect inhibitors.
1.3.1. Indirect allosteric inhibitors
Indirect inhibition through antithrombin activation has been a mainstay of this category.
Precipitated by the advent of heparin, which was later found to activate the inhibition of a
13

number of enzymes in the coagulation cascade. However, antithrombin activation was
considered as the primary mode of action. Several decades later heparin continues to be a
major contributor in this class. Innovative design strategies and the discovery of other
serpins, like heparin cofactor II, promise to be the new strategies towards developing
more, safer indirect anticoagulants.
Antithrombin activators
Antithrombin: structure and kinetics of inhibition
Antithrombin, as the name suggests, is a physiological inhibitor of thrombin in addition
to a variety of other coagulation enzymes like FXa and FIXa. This highlights the
importance of this serpin. Physiologically, antithrombin exists as 58,200 Da plasma
protein with relatively slow rates of inhibition of its target on its own.20 However,
coupled to its high plasma concentration (~2.3 µM) and its known interaction with cellsurface polysaccharide species like heparan sulfate, results in an acceleration of its
activity culminating in a rapid inhibition of procoagulant proteinases.20 Homozygous
antithrombin knockout mice appears to be incompatible with life, however heterozygous
mutation produces structurally defective variants.21,22 The crystal structures of
antithrombin in both the apoform and in presence of pentasaccharide have been solved,
further providing insight into the function of this important enzyme.22 A glycoprotein
with 432 residues, it is known to possess four glycosylated Asn residues in its stable
major α-antithrombin form. β-antithrombin, also known as the minor form, is not
glycosylated at Asn135. The crystal structure indicates nine α-helices surrounding three
β-sheets.23-25 The presence of a dominant five-stranded β-sheet A approximately in the
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center of the inhibitor and an exposed 15–residue sequence comprising the reactive bond
Arg393-Ser394, also known as the reactive center loop (RCL), are the two distinctive
features.26-28 Another unusual feature seen only in AT and HCII is the presence of two
residues, P15-P14 (Gly379-Ser380) at the N-terminal end of the reactive center loop,
which are inserted as a short β-strand between strands 3 and 4 of the β-sheet A in the
inhibitor (Figure 5A).

15,29

This partial insertion of the RCL plays a major role in the

process of proteinase inhibition. The structure of antithrombin cleaved at the reactive
bond shows the complete insertion of RCL as strand 4a in β-sheet A (Figure 5B) with the
remainder of the protein remaining largely unchanged. This structural change initiates an
approximately 70Å movement of the P1 residue from the top of the molecule to the
bottom.30,31 This dramatic conformational change yields an additional thermodynamic
stabilization of the molecule and is considered to be a critical event in the disruption of
the catalytic triad of a target proteinase, eventually resulting in its inactivation.32-35
This mechanism has been widely referred to as the serpin mousetrap mechanism, where
the serpin (AT) acts as a bait to trap target enzymes like FXa, FIXa and thrombin (E) in
an equimolar, covalent inactive complex (E*-AT*) (Figure 6). Initial interaction between
the RCL and the proteinase active site forms a Michaelis complex (E:AT), which is then
followed by the rapid cleavage of the P1-P1’ scissile bond in the RCL to form an acylated
intermediate (E*-AT*). Another competing reaction known as the substrate pathway,
involves rapid cleavage of the acylated enzyme (E-AT) to give the free enzyme and
substrate. This does not contribute during normal experimental conditions.15

15

A

B

Figure 5. Ribbon diagram of native (A) and cleaved (B) plasma antithrombin. The
structure of plasma antithrombin was obtained from PBD (pdb id‘1ath’) (Figure adapted
from Reference 10)
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Figure 6. A model of the serpin ‘mousetrap’ mechanism of inhibition. (Figure adapted
from Reference 10)
Heparin induced activation of antithrombin
Serpins are generally known to inhibit their target enzymes by diffusion controlled
acceleration rates of ~106-107 M-1 sec-1. Uncatalyzed rates of antithrombin inhibition,
however, are drastically low with in vitro rates of ~7-11 x 103 M-1 sec-1 for thrombin and
~2–3 x 103 M-1 sec-1 for FXa.36-39 The native structure of AT highlights a peculiarity in
the RCL, which exhibits partial insertion forcing P1 and other important residues to adopt
a conformation that hinders the interaction with enzymes like thrombin and FXa. Owing
to this, the anticoagulant effect of antithrombin is suboptimal physiologically.40 Heparin,
a natural linear polysaccharide, was identified to possess anticoagulant effect in 1916.41 It
was later deciphered that this effect was seen due to its acceleration of antithrombin
inhibition of a number of coagulation enzymes as shown in (Table 2).26 Since then much
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of research has been dedicated understanding the mechanism of its action and developing
agents, which could mimic this interaction.
Mechanism of heparin activation
Heparin is known to accelerate antithrombin by two distinct mechanisms, namely the
conformational and the bridging mechanism. The conformational change mechanism
involves a major change in the structure of antithrombin on interacting with heparin,
which accelerates its inhibition of FIIa and FXa. In the case of the AT-FXa system,
binding of the highly specific heparin pentasaccharide H5 to heparin, at an exosite
produces a conformational change in the RCL and β-sheet C. The partially inserted P1P1’ reactive center and an exosite on AT is now exposed, which is then better recognized
by FXa, resulting in accelerated cleavage of the P1-P1’ bond and rapid formation of
covalent inhibited complex.32,39,42,43 This phenomenon is also seen with other enzymes,
but it is more important in the inhibition of FXa.
In contrast, the bridging mechanism is found to be crucial in the acceleration of
thrombin inhibition. Specific binding to antithrombin of heparin H5 sequence, present in
the full-length heparin is followed by thrombin binding to the same chain at non-specific
sites to form ternary complex comprised of antithrombin-heparin-thrombin as shown in
Figure 4. This is then followed by diffusion of thrombin along the polyanionic heparin
chain, resulting in ~2000 –fold inhibition under physiological conditions.17,44,45 A
polysaccharide of ~18 residue saccharide units is required to simultaneously hold
thrombin and antithrombin for accelerated inhibition. Thus, in this case the H5 sequence
alone cannot potentiate inhibition. Recent evidences however suggest that such a
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mechanism could be used by the AT-FXa system too, however this is seen in the
presence of Ca2+ with full-length heparin. Similarly, UFH is also known to accelerate AT
inhibition of FIXa 300-500-fold through the conformational mechanism and ~1000-fold
using the bridging mechanism.43 The mechanism of action for thrombin, FXa and FIXa is
summarized in (figure 4).10,46
Heparin binding site
The allosteric heparin binding exosite is located around 20 Å away from the RCL in AT.
This exquisitely structured site specifically recognizes the H5 sequence from a variety of
structurally different heparin chains. The heparin-binding site is predominantly positively
charged made up of the positively charged residues of helices A and D, and the
polypeptide N-terminus. The crystal structure of antithrombin with the pentasaccharide
sequence has been solved and indicates four important residues (Arg47, Lys114, Lys125,
and Arg129) and the domain called the pentasaccharide binding site (PBS).22,47-51 Fulllength heparin called the extended site formed by residues Arg132, Lys133, and Arg136
at the C-terminal end of helix D and is known as the extended heparin binding site
(EHBS).47 The interaction of H5 with the PBS induces conformational change with
allosteric effects. This allostery is seen on both sides the RCL end as well as the heparin
binding site end. The P1-P1’ bond (Arg393-Ser394) is the target for proteinase
cleavage.52,53 Antithrombin inhibits a number of coagulation enzymes and the interaction
with heparin is know to accelerate it to varying degrees towards inhibition of other
proteinases as seen in (Table 2). Though this provides for a major block in the
coagulation activity, it could however lead to bleeding risk. Therefore, controlling the
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activation towards its intensity and specificity of target enzyme can help develop safer
and more useful anticoagulants.
Table 2. Acceleration rates of antithrombin towards inhibition of proteinases in the
presence of heparin and the mechanistic contribution of this acceleration.26
Serpin Proteinase

Bridging

Conformational

Max rate (M-1 s-1)

AT

Thrombin

~2400-fold

~1.7-fold

~3.7 x 107

AT

Factor Xa

~70-fold

~300-fold

~4.4 x 107

AT

Factor IXa

~600-fold

~700-fold

~2.0 x 107

AT

Trypsin

~2.2-fold

~3.2-fold

~1.4 x 106

Classes of antithrombin based anticoagulants
Heparin is the one of the most widely used anticoagulant, impelling enormous research
activities towards discovering/designing newer agents, aimed at both improving on
heparin as well as refining the selectivity towards targeting specific enzymes. These
molecules can be classified into 1. Heparin-based activators 2. Heparin-pentasaccharide
DEFGH and its variants 3. Nonsaccharide-based activators.
Heparin-based activators
Heparin is a glycosaminoglycan (GAG), which continues to be a mainstay of
anticoagulant therapy for decades, however advances over the past years have yielded
worthy successors to this pivotal drug. Structurally, heparin is a polysaccharide
consisting of chains ranging from 5,000-40,000 in weight, with an average of ~14,000.
Heparin is predominantly made up of alternating unit of glucosamine or uronic acids.
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These are sulfated at varying levels, with N-sulfation and/or sulfation at 2, 3, or 6
positions. The uronic acids generally involved include the β-D-glucuronic acid or α-Liduronic acid with varying degree of sulfation (Figure 7).54-57 The high degree of sulfation
makes heparin a highly negatively charged molecule. The heterogeneity in structure,
molecular weight and polyanionic character make it a novel and equally challenging class
of anticoagulant.
The diversity in heparin was moderately reduced through the use of enzymatic and
chemical approaches in developing smaller heparins with an average molecular weight of
~4,000 – 6000, also known as the low molecular weight heparins (LMWH).58,59 A variety
of these have been made available commercially as seen in (Table 3). Synthetic variants
using natural polysaccharide like hyaluronic acid, chitosan, dextran, galactomannan and
fucan have been sulfated but, these fail to replicate the activity seen with heparin.60-64

Figure 7. Structure of heparin.
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Table 3. Comparative properties of low molecular weight heparin preparations.15
Brand name

Manufacturer

Key reagent in

MR

depolymerization

Ratio antifXa: anti-IIa

Ardeparin

Wyeth-Ayerst US

Peroxides

5,300

2.0

Dalteparin

Pharmacia, US

Nitrous acid

6,000

1.9 – 3.2

Enoxaparin

Aventis, US

Alkali

4,500

3.3 – 5.3

Nadroparin

Sanofi, France

Nitrous acid

4,300

2.5 – 4

Reviparin

Knoll AG, France

Nitrous acid

3,900

3.6 – 6.1

Tinzaparin

Leo Labs, Ireland

Heparinase

6,500

1.5 – 2.5

Anticoagulant heparin, however, has been associated with numerous complications. One
of the major concerns is, that of heparin induced thrombocytopenia (HIT). Most of these
complications have been attributed to non-specific interactions and to major structural
differences. Another problem associated with the heparin is the lack of ability to
inactivate clot bound thrombin, which is attributed to the thrombin binding to γ-fibrin at
exosite II, thus blocking the heparin-binding site.65-70
Lower molecular weight heparins have a significantly lower bleeding rate but, they do
not completely eliminate the bleeding risk. Different methods of preparations are known
to bring about variations in their anticoagulant properties, prompting the FDA to suggest
each clinical LMWH be treated as an unrelated independent drug.71-76 Nevertheless,
newer heparins continue to be developed at a frantic pace. Technological advances in
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related fields have led to expectation of developing structurally and biologically superior
heparins.
Heparin oligosaccharides
The heparin pentasaccharide sequence DEFGH has been identified as the specific tight
binding sequence and is known to bring about a conformational modification of
antithrombin, which produces acceleration in it inhibitory properties. Structurally, it is
made up of two domains, the trisaccharide DEF and the disaccharide GH domain. The
disaccharide sequence consisting of →4)IdoAp2S (1→4)GlcNp2S6S (1→ is known to be
the most abundant disaccharide sequence in heparin, whereas the trisaccharide sequence
consisting of GlcNp2S,6S(1→4) GlcAp(1→4)GlcNp2S,3S,6S is the least abundant
sequence in heparin.77,78 The most characteristic feature includes the presence of a central
glucosamine residue, F, consisting of three sulfates at 2-, 3-, and 6-positions, which is
rarely present outside the pentasaccharide H5 sequence. Both these domains play
different roles with the trisaccharide playing an important role in inducing
conformational changes while the disaccharide is involved in stabilization of this change
and improving the overall affinity of H5. The crystal structure of the pentasaccharide
with antithrombin has been obtained and this provides for insights of the residues
involved at a molecular level as seen in (Figure 8).15
The pentasaccharide is known to produce acceleration of selective AT inhibition of FXa
alone. This is due to the ability of the pentasaccharide to utilize the conformational
mechanism of activation alone, which is a major player in the activation of AT towards
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FXa inhibition. Thrombin inhibition, on the other hand, utilizes the bridging mechanism
and thus is not inhibited.
The major complications in heparin generally arise from its non-specific interactions,
which were primarily attributed to its complex structure. Reducing this complexity by
chopping down the size of heparin to oligosaccharides like heparin pentasaccharide has
helped improve this specificity. Since the discovery of the pentasaccharide numerous
efforts have been made to develop even better oligosaccharide units. Some of this work
explored natural variants of the pentasaccharide, (Petitou and coworker). Similarly,
synthetic variants were designed to conduct a structure activity relationship study to
design more potent sequences. A few of these efforts have been summarized in (Figure
9).

Figure 8. Crystal structure of pentasaccharide with antithrombin displaying the
interaction with antithrombin. (Figure adapted from reference 10)15,25
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Synthetic nonsaccharide based activators
The hypothesis that synthetic small molecules could mimic the activity of heparin has
recently resulted in efforts aimed at the development of small molecule activators of
heparin and heparin pentasaccharide. These have utilized computational tools like HINT
to obtain molecules that could structurally resemble the heparin trisaccharide sequence
DEF, which was the smallest oligosaccharide sequence to still possess activity. On this
basis, a group of small molecules were identified, followed by a series of structural
screens, from which (-)-epicatechin sulfate was found to be small molecule activator of
antithrombin. Using a similar approach several other molecule where designed with a
maximum of ~80–fold activity obtained. However, the detailed competitive binding and
molecular binding studies indicated that these molecules bind to the extended heparinbinding site (EHBS) (Figure 7). Thus, developing agents, which could target the
pentasaccharide, binding site or both the pentasaccharide and the extended heparin
binding sites could result in a more active molecule.58,59,79-82
Heparin co-factor II activators
Heparin cofactor II (HCII) is a 65.5KDa plasma protein that belongs to the serine
protease inhibitor (Serpin) family. Since its initial discovery in 1974 by Bringinshaw and
Shanberge, little information has been obtained despite its high plasma concentration of 1
µM.83,84 Initially named heparin cofactor A and other names, such as antithrombin BM,
dermatan sulfate cofactor and leuserpin-2, it was eventually named heparin cofactor II by
Tollefsen and Blank.85 Its major inhibitory activity was observed against thrombin in the
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presence of dermatan sulfate, which produces a 1000–fold acceleration in inhibitory
activity.
DEFGH

X=NHSO3

Y=COO-

Y’=COO-

D’EFGH

X=NHCOCH3

Y=COO-

Y’=COO-

DE’FGH

X=NHSO3

Y=COOCH3

Y’=COO-

DEFG’H

X=NHSO3

Y=COO-

Y’=H
DEFGH’

DEFGH-NGA

c--DEFGH

Figure 9. Structure of natural pentasaccharide DEFGH derivatives.15
Structure, function and the kinetics of inhibition by heparin cofactor II
The crystal structure of heparin cofactor II has been solved both in the native form and in
the presence of thrombin. This reveals some structural insights into the functioning of this
serpin. HCII is composed of 480 amino acid residues. On a three-dimensional level, it is
structurally quite similar to AT, with a six-stranded β-sheet A due to the partial
incorporation of the RCL that effectively reduces its flexibility and accessibility to
proteolytic attack. Superposition of AT and HCII structure indicated a deviation in
RMSD of 1.8Å, consistent with similar functions, which involves the expulsion of the
RCL to further inhibit circulating serine proteases. A major difference between AT and
HCII is the presence of Leu at the P1 position instead of the Arg residue normally seen in
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serpins.

The heparin binding sequences in HCII obtained on sequence alignment

indicates the conservation of similar residues. The N-terminal acidic tail, which
comprises 160 amino acids, consists of two hirudin-like domains, EDDDY*LD and
EDDDYID. Both these consists of several acidic amino acids and a sulfated tyrosine,
which are responsible for interaction with exosite I of thrombin.29
Physiologically, despite its high concentration, HCII does not seem to be vitally
important, with individuals predisposed to HCII deficiency not showing an increased risk
of venous thrombosis. Recent studies have postulated that HCII plays the role of an
adjunct to AT in hemostasis regulation. HCII, however seems to play a major role during
pregnancy with studies indicating that HCII deficiency is embryonically lethal. Increased
HCII levels during pregnancy further add to this claim. HCII has also been shown to play
a major role in vascular injury with high levels of HCII showing a decrease in
atherosclerosis and restenosis, whereas reduced levels have been shown to produce
increased cardiac events.86-89
Comparable to AT, HCII is quite similar in its mechanism of inhibition of serine
proteases, the only difference being the presence of Leu at P1 instead of an Arg,
generally seen in serpins. HCII is known to inhibit thrombin in addition to other proteins
like chymotrypsin and neutrophil cathepsin G. Its rate of inhibition of thrombin is very
slow (600 M-1s-1). Thrombin specificity is conferred by the presence of two hirudin-like
domains in the N-terminus of HCII. Unlike AT, which is substantially activated by only
heparin, HCII shows a ~1000–fold increase in activation in the presence of heparin,
heparan sulfate and dermatan sulfate and several other types of polyanions such as
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polysufates, polyphosphates, and polycarboxylates (Table 4). These agents function
through the release of the RCL from in the partially inserted state to a fully exposed state.
Table 4. Second order rate constants of proteases inhibition by human HCII in the
presence of various cofactors.26,90
Serpin Target Proteases
HC-II

Cofactor

Second order rate k2 (M-1s-1)

-

6 x 102

UFH

5 x 106

LMWH

5 x 106

Dermatan sulfate (DS)

~5 x 106

Hexasaccharide DS

107

Chondroitin sulfate E

2 x 106

Thrombin

Dextran sulfate

5 x 106

Thrombin

Sucrose octasulfate

~106

Chymotrypsin

-

2 x 104

Cathepsin

-

2 x 102

Heparin cofactor II-dermatan sulfate interactions
The inhibition of thrombin by HCII is accelerated nearly 1000-fold in the presence of DS.
Though AT is structurally similar to HCII, with similarities in the heparin binding site,
nevertheless heparin pentasaccharide DEFGH binds HCII poorly in comparison to its
affinity for antithrombin.91 Dermatan sulfate produces acceleration by a basic bridging
mechanism, providing a template for HCII and thrombin to bind. Structurally, DS is a
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linear polymer of D-glucuronic acid or iduronic acid alternating with N-acetyl–Dgalactosamine residues. Like heparin, DS is heterogeneous as a result of a varying
degree of O-sulfation and the two types of uronic acid residues.92 Physiologically,
dermatan sulfate is found in the vessel wall. The surface of fibroblasts and vascular
smooth muscle cells generally contain dermatan sulfate proteoglycans. A subpopulation
of oligosaccharides obtained by partial depolymerization of DS binds to HCII at
physiological salt concentration. In a manner similar to heparin pentasaccharide H5, a
distinct small fragment of dermatan sulfate binds with increased affinity to HCII. This
hexasaccharide contains three L-iduronic acid (2-SO3) N-acetyl D-galactosamine (4
and/or 6-SO3) disaccharide units.90
Heparin cofactor II as a target
The DS-HCII system has number of important physiological roles. Unlike AT, HCII in
the presence of heparin or dermatan sulfate is only activated towards thrombin inhibition.
This unique specificity can be used to develop agents with reduced bleeding risks. HCII
deficiency does not appear to enhance risk for thrombosis and at the same time it
prevents arterial thrombosis. A major advantage of HCII activation is its ability to target
clot-bound thrombin but not other coagulation proteases and its postulated that HCII
contributes to ~20-30% of thrombin inhibition in coagulation, a feature not seen in
AT.90,91
All these advantages point towards the development of HCII activators to produce
an indirect pathway of coagulation regulation. Numerous attempts are now being made
toward developing agents targeting HCII. Investigations include oversulfated dermatan
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sulfate, chitosan polysulfate, fucoidan, clam dermatan sulfate, green algae sulfated
polysaccharide and fucosylated chondroitin sulfate. Smaller oligosaccharides like sucrose
octasulfate have also been recently identified as a HCII activator.93
1.3.2. Direct allosteric inhibitors
Direct inhibitors are generally agents, that target the catalytic triad located in the active
site of serine proteases. However, with the growing knowledge and the discovery and
understanding of other allosteric sites in the serine proteases, these sites are is now a
subject of interest for designing agents, that could target these sites and thus inhibit the
coagulation enzymes directly. The hypothesis behind this strategy is that the active sites
of most serine proteases are quite similar, thus making it difficult to develop selective
agents. Allosteric sites structurally however, are relatively different for these enzymes
and could therefore be utilized in developing more selective agents. Additionally,
controlled modulation of these enzymes through allosteric inhibition offers for lesser
risks. Nevertheless a number of selective thrombin and FXa inhibitors have been
discovered with few recently making it to the market.
Downstream targets
Direct thrombin and FXa inhibitors
Thrombin and FXa are the major downstream targets of various anticoagulant therapies.
Structurally, these are quite similar enzymes and have a similar mechanism of action.
Agents utilizing these targets are now slowly replacing unfractionated heparin (UFH) in
the market.
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Thrombin is a serine protease with a three dimensional structure similar to most
serine proteases. Targeting thrombin directly produces a substantial degree of coagulation
through additional prevention of thrombin-mediated feedback of factors FV, FVIII, FXI,
and FXIII. Numerous crystal structures of both the native form and the co-crystallized
form in the presence of an inhibitor have been deposited in the protein data bank (PDB).
Thrombin could either be targeted at its active site or the two-polyanionic exosites and
the Na+ binding site, which serve as allosteric targets. Numerous agents have been
discovered and/or designed that specifically target thrombin. Table 5 summarizes a list of
these agents.
Directly inhibiting FXa is another approach, which is gaining popularity with
many of these agents making it to the clinic recently. Directly targeting FXa has been
hypothesized to be more effective then thrombin inhibition, due to the fact that one
molecule of FXa is responsible for the generation of 1000 thrombin molecules.94,95 Thus,
regulation of thrombin production rather than inhibiting it also ensures that the natural
clotting process post surgery can function more smoothly. Two new FXa inhibitors,
rivaroxaban and apixaban have recently been approved for use clinically.96-99
Table 5. List of direct thrombin inhibitors.
Drug name

Binding site

Melagatran

Active site

Dabigatran

Active site

Hirugen

Exosite I

Bivalirudin

Exosite I
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Direct agents, however, do not completely eliminate the risks observed with indirect
agents. Risk of bleeding is a major complication in these agents, though the intensity is
decreased to safer levels but not completely eliminated. Certain natural agents like
hirudin have added problems like anaphylaxis while other agents produce liver toxicity.
Thus, the current challenge to overcome in the design of these agents involves
eliminating bleeding risk, liver toxicity and histamine release, while maintaining good
oral bioavailability and duration of action.
Novel upstream targets
Major bleeding risks have led to the hypothesis that utilizing an upstream enzyme could
produce controlled inhibition without producing the deleterious effects of other stronger
downstream agents. Targeting upstream enzymes from the intrinsic pathway, particularly
FXIa, has been postulated to potentially achieve a safer degree of anticoagulation.
Structure and function of FXIa
FXIa is a major player in the intrinsic pathway. It is involved in the activation of
FIX to FIXa, which eventually activates FX to FXa. The crystal structure of its zymogen
form, FXI, and the catalytic domain of its active form (FXIa) have been solved, thereby
providing insights into the overall structure and working of this enzyme. Physiologically,
it exists as a homodimer linked by a disulfide bond, with each monomer consisting of 607
amino acid residues. Its three dimensional structure is analogous to a cup and saucer
arrangement with the catalytic domain surrounded by four apple domains (Figure 10).
These are responsible for the recognition of FIX in the coagulation cascade in addition to
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heparan sulfate, GPIb and other ligands. Like thrombin and FXa, FXIa also consists of a
heparin-binding site in the A3 apple domain, and strikingly another heparin binding site
in the catalytic domain.100-102
C321

AL

AS

AL

H2
T

H1
FIX

Gp1b

HK

Figure 10. The structure of zymogen FXI. The catalytic domain is in white. Sites of
residues implicated in ligand binding are red for thrombin (T), green for HK, black for
GPIb, blue for heparin sites (H1 and H2), and orange for FIX. Positions for the activation
loop (AL) cleavage site (Arg360-Ile370) residue Ile370 and active site (AS) residues
Ser557, Asp462, and His413 are shown in purple. (Figure adapted from Reference 94)
Targeting FXIa
The utility of FXIa as a drug target has been revealed by a number of in vitro
models of coagulation. Additionally, studies on its deficiency in humans and in animal
models of thrombosis and hemostasis has further supported the claim that it could indeed
serve as a safer target to modulate the coagulation system. In vitro studies have measured
the action of FXIa on both the extrinsic and the intrinsic pathways by utilizing the PT and
the APTT assays respectively. These studies displayed the importance of FXIa in the
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intrinsic pathway, where FXIa inhibition affected clot formation in the APTT assay. This
further supports the inference that FXIa is more essential in the amplification than in the
initiation of coagulation.103,104 FXI deficiency, which is seen in a condition called
hemophilia C, generally observed in the Ashkenazi Jews, was found to show minor risk
to bleeding. Bleeding in this condition was only seen on occurrence in response to
surgery or trauma, however in women the deficiency did not affect pregnancy or
delivery. This, indicates that FXI is more important in conditions of thrombosis and does
not necessarily affect hemostasis.105-107 The occurrence of ischemic stroke was found to
be significantly reduced in FXI-deficient patients.108 Genetic studies in mice have
demonstrated that FXI-null mice do not develop clots in FeCl3-induced carotid artery
model, additionally showing no effect on bleeding time.109 These observations, validate
the use of FXIa inhibition as a target to develop anticoagulants.
FXIa inhibition as an anticoagulant target is a rather new premise, with a review
of literature revealing of very few molecules targeting this enzyme. These are argininecontaining acyclic peptidomimetics, guanidine-containing arylboronic acid and natural
products like clavatadines A and B, β-lactam derivatives, and amidine containing
macrocyclic indoles.104,110-115 All of these recognize residue in the catalytic triad of FXIa
active site. However, there exist minute differences in the active sites of various serine
proteases and thus the advent of allosteric site inhibitors. Two heparin binding site exist
on FXIa as mentioned earlier, with the one on the catalytic domain showing a 100–fold
greater affinity and an allosteric mechanism of action, whereas the one in the A3 domain
is postulated to have a more template based mechanism (Figure 10).116,117 These could be
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targeted to develop allosteric inhibitors of FXIa, with the potential advantage that the
heparin-binding site of all serine proteases is structurally different and thus allows for use
of these differences in developing selective agents.103
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CHAPTER 2: RATIONALE
Allostery involves conformational and functional transitions in individual protein
molecules.1 In a more classic sense, molecules, which function in this fashion are based on
the principle of influencing the activity of an enzyme by binding to a site remote from the
active site of the enzymes. Numerous reports of systems functioning by this route have
been reported and well studied.
Glycosaminoglycans (GAGs) have been subjected to extensive studies because of
their prevalence in nature. Numerous functions have been sustained by the plethora of
protein-GAG interactions, which have been recognized and continue, to be, identified
thereby propelling our understanding of this complex yet highly important system of
interactions. A majority of this study is focused on protein interactions with heparin. The
steady commercial availability of heparin and its use in fractionation and heparinsepharose affinity chromatography make it a well-studied polymer. The presence of
heparan sulfate in cells and their subsequent interactions in numerous physiologically
relevant interactions has also garnered interest. The importance of heparin in the
coagulation system has been a hot topic for research with the advent of heparin as one of
the earliest anticoagulants and it continues to be utilized at present.
The anticoagulant effect of heparin led to widespread studies aimed at deciphering
the mechanistic and structural aspects of this interaction. The antithrombin-heparin
interaction can now be considered the paradigm for studying GAG-protein allosteric
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interactions. Studies indicated the mechanism with which heparin interacts with AT to be a
conformational/bridging based interaction. Similarly, a number of serine proteases have
been reported to possess a highly positive heparin-binding site, including FXa, thrombin,
FXIa and FIXa.
The complexity of heparin interactions with proteins and the resulting functions it
alters can be attributed to the phenomenal structural diversity in heparin polymers and their
sulfation pattern. Numerous efforts have been made to reduce this complexity through the
identification of smaller more defined units. The heparin pentasaccharide has been the
most notable example of a highly specific unit with well-studied interactions. However, the
interactions of heparin with other serpins like HCII and serine proteases like thrombin,
FXa and FXIa have not been thoroughly understood. Numerous research efforts have
therefore been employed to obtain a comprehensive understanding of both the mechanistic
and structural diversity of heparin.
The rationale of the current work is based on improving our understanding of this
incidence. The studies address two questions:
1. Can computational strategies be devised to exploit the structural diversity of
heparin sulfate in activating serpins.
2. Can allosteric sulfated quinazolin-4(3H)-ones be developed as more potent
inhibitors of FXIa?
These questions have been approached through two projects addressing question 1 and one
project addressing question 2.
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a. Novel hexasaccharide based activators of heparin cofactor II and antithrombin
(Discussed in chapter 3)
b. Differential recognition of coagulation proteins by a heparan sulfate containing 2-Osulfated glucuronic acid (Discussed in chapter 4)
The goal of both these projects was to develop computational strategies that could utilize
the structural information for the proteins efficiently to recognize sequences with high
affinity and specificity. This was followed by an experimental validation. Project 1a,
involves the computational design of heparin-based hexasaccharide sequences followed by
the selection of high affinity and specificity structures through the dual-element algorithm
developed in our laboratory. The algorithm helped recognized two specific sequences,
which could be utilized as novel dual activators of HCII and AT.
Project 1b takes into account the structural enormity of the heparan sulfate
disaccharide library and utilizes very rare sequences indicated to be of high interests
through our computational studies and further reported occurrences and mechanistic
evaluations. This is followed by the enzymatic synthesis of a polymer rich in the rare
disaccharide sequence and its mechanistic evaluation. The questions answered through the
evaluation could help unearth newer interaction in addition to understanding the structure
prevalence in nature.
Question 2 utilizes a completely different approach at selectively targeting the
heparin-binding site in FXIa. FXIa, which belongs to the intrinsic coagulation pathway,
has been increasingly recognized as a safe alternative to other downstream targets. The
active site of serine proteases is conserved and is comprised of a catalytic triad making it
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difficult to design selective agents by targeting specific differences in the active site. The
heparin binding sites of such proteins are decorated with positively charged arginine/lysine
residues, however the hydrophobic domain bordering these have been hypothesized to be
different. We therefore utilized the dual element strategy, using a molecular design
containing an electrostatic element and a hydrophobic moiety. The electrostatic moiety
should recognize the heparin-binding site, the hydrophobic moiety could be used to
identify complementary binding sites, that selectively target a specific protein. Our
approach has been deemed successful through the synthesis and identification of sulfated
quinazolinone dimers. We further this approach through the identification of more potent
and selective agents, while utilizing these advances to gain a mechanistic understanding of
these molecules.
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CHAPTER 3: NOVEL HEXASACCHARIDE BASED ACTIVATORS OF
HEPARIN COFACTOR II AND ANTITHROMBIN.

3.1. INTRODUCTION
GAGs have been ubiquitously found in nature.118,119 Structurally, these are polymers of
alternating glycosamine and uronic acid residues, which are irregularly decorated along
the chain with either sulfates or acetate moieties. Heparan sulfate, chondroitin sulfate,
dermatan sulfate and hyaluronan comprise the most prevalent GAGs found in nature in
addition to numerous other GAGs localized in various tissues. These are increasingly
being recognized to play critical roles in many biological processes, including
hemostasis, growth and differentiation, immune responses and pathogen invasion.120-123 A
phenomenonal structural diversity exists among the GAGs and these are introduced in a
spatiotemporal fashion by utilizing a template-free arsenal of 16 enzyme isoforms.122
Heparan sulfate and heparin, which reportedly are the most extensively studied,
are primarily composed of alternating 1→4 linked uronic acid and glucosamine residues
that are decorated with sulfate and N-acetyl groups. Theoretically, 96 different
disaccharide sequences are possible for H/HS arising from uronic acid (UAp) residues
that can bear either an –OH or a –OSO3− group at their 2- and 3-positions and
glucosamine (GlcNp) residues that may contain either an –OH or -OSO3− group at their
3- and 6-positions, as well as either an –NH3+, –NHSO3− or –NHAc group at its 2position. However, only 23 sequences have been identified in nature.124 The structural
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complexity is demonstrated by a simple calculation where 0.8 billion distinct sequences
are possible for a HS oligomer containing six repeating disaccharide units. For a
hexapeptide this number is 64 million, while a hexanucleotide could be one of the 4096
sequences.125 Further complications arise from the conformational variability of the
iduronic acid (IdoAp) residues, which exist in multiple forms of which 1C4 and 2S0 are
usually preferred.126 These combinations of structural and conformational possibilities
make GAGs a very difficult prospect to study.
Computational analysis might serve as a powerful approach to the complex protein-GAG
interactions. However, this is not a straightforward approach with the polyanionic nature
and the poor surface complementarity posing major obstacles.127 However, our recent
efforts have yielded a combinatorial virtual library screening (CVLS) approach, which
utilizes the genetic algorithm-based automated docking program GOLD.91,128 The
technique was efficiently utilized in recognizing the binding mode of heparin
pentasaccharide, which is consistent with that seen in the crystal structure.129 The success
of this approach for this pair suggests its utility in similar systems.
Out of contrast to the vast heparin structural diversity, the heparin pentasaccharide
sequence is the only one that targets AT with a higher specificity. This sequence has been
extensively studied and numerous structural activity relationships have been performed to
recognize the features essential for its specificity to AT and the resultant activation.
Similarly, heparin cofactor II has been studied widely, due to its structural and functional
similarity to AT and the possible advantages it offers in terms of its safety and selectivity
profile.86,88,92 An alternative oligosaccharide sequence can similarly be devised for this
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serpin too. With this in view, studies conducted reported a hexasaccharide sequence as
the minimal moiety required to interact with HCII.92,130 Further, studies however fail to
register the same level activation for this system.130 The concept however has attracted a
flurry of research aimed towards identifying such a sequence. The CVLS approach could
serve as good starting point to identify such sequences for the HCII-dermatan sulfate
system in a manner akin to the AT-heparin pentasaccharide system. However, the
syntheses of simple oligosaccharides have been found to be a painstaking process, which
incorporates numerous steps.16,131-133 Consequently, in this work we have utilized our
computational approach and successfully identified sequences with the potential to be
utilized as an anticoagulant functioning through the unique HCII-thrombin system in
addition to the AT-FXa system.
3.2. RESULTS
3.2.1. Computational studies (Work performed by Drs. Raghuraman, Mosier and
Sankaranarayanan)
Structure of the Activated Form of Heparin Cofactor II
Two experimentally determined structures of heparin cofactor II are available, native and
S195A thrombin-complexed.29 The overall structure of native HCII is similar to that of
native antithrombin. Superposition of the structure of native HCII on that of native
antithrombin (PDB file: 2ant)25 gives a RMSD of 1.8 Å for 352 equivalent Cα atoms (not
shown). Likewise, superposition of Cα atoms of the residues that define the heparinbinding site in antithrombin, i.e., Arg46, Arg47, Lys114, Lys125, Arg129, Arg132 and
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Lys133, with corresponding residues in heparin cofactor II results in a RMSD of 1.5 Å
indicating a high degree of similarity between the two native serpins.
The structure of GAG-activated heparin cofactor II is not available as yet.
However, the structure of the serpin in complex with S195A thrombin displays extensive
similarities with that of the heparin pentasaccharide-activated antithrombin (Figure 11).
The S195A thrombin-complexed HCII shows an expelled reactive center loop (RCL), as
found in pentasaccharide-activated antithrombin.22,134 The reason for the expulsion of the
RCL appears to be the extensive exosite interactions that the RCL makes with S195A
thrombin.

Likewise,

exosite

interactions

also

stabilize

the

heparin-induced,

conformationally activated antithrombin, as borne out in experiments with factor Xa and
factor IXa, its conformational activation targets.42,135 Thus, the overall structure of HCII
in the S195A thrombin-complexed state is similar to that of the pentasaccharide-activated
antithrombin.
Further evidence that these forms are nearly identical comes from the
superposition of the corresponding Cα atoms. Figure 11 shows the superimposed
activated forms of the two serpins. The RMSD in Cα atoms of the core amino acid
residues was found to be 2.4 Å suggesting significant similarity in the orientation of most
structural domains including β-sheets and helices. More importantly, the RMSD for
corresponding basic residues in helices A and D was found to be 1.5 Å indicating a high
degree of similarity between the two activated forms in this region. These structural
similarities indicate that the S195A thrombin-complexed HCII is likely to be the H/HSactivated form of the serpin.
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However, differences exist between the two activated serpins in the relative
orientation of helices A and D, and in the extension of RCL. Whereas A helices (hA)
superpose nearly completely, the D helices (hD) display a significant ~30° angle between
the two serpins (Figure 11). Likewise, the RCL in the activated forms show a
significantly greater extension of the loop in the S195A thrombin-complexed HCII than
in the pentasaccharide-activated AT (Figure 11). In addition, helix D of heparin cofactor
II contains an additional electropositive residue, Arg184, which has no counterpart in
antithrombin. Thus, although the two serpins in their native and activated forms are
nearly equivalent, subtle differences are evident. Despite these differences, the S195A
thrombin complexed HCII structure is very similar to the pentasaccharide-activated AT
structure and is a good model for investigation of H/HS interactions, especially
considering that the structure of GAG-activated HCII is unknown.

44

hF
hD

RCL

hA

Figure 11. Comparison of the structure of S195A thrombin-complexed heparin cofactor
II with heparin pentasaccharide activated antithrombin. Core polypeptide sequences,
devoid of residues of the N-terminus and the RCL, were to give an overall RMSD of 2.4
Å. Note the small rotational difference in helix D axis and at the N-terminal end of helix
A between the two proteins, while the expulsion of RCL in heparin cofactor II is much
greater than that in antithrombin. Antithrombin ribbon is shown in green and red (hD, hA
and RCL), while HCII is shown in gray and yellow (hD, hA and RCL).
Filtering of sub-optimal HS sequences from a library of 46,656 sequences
Computational docking approaches represent a powerful means of assessing binding
affinity, specificity and binding geometry. Yet, modeling GAGs is challenging because
the high negative charge density tends to induce false positive recognition. In addition,
most GAG-binding sites on proteins are surface–exposed and shallow, which encourage
poor complementarity.136-142 Our previous CVLS protocol was applied to a small library
of H/HS sequences (~7,000 sequences) and screened a limited domain of 3D space to
assess ‘specificity’ of binding.128 However, the repertoire of nature’s sequences is huge,
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of which the majority are never studied rigorously. Recently, we have designed a robust
genetic algorithm-based combinatorial virtual library screening approach that utilizes a
dual-filter process to identify hexasaccharide sequences in heparin that recognize
antithrombin with high specificity. This sequential dual-filter algorithm utilizes GOLD
score, a measure of ‘affinity’, as the first filter, followed by convergence of binding
geometries, a measure of ‘specificity’, as the second (Figure 12).
In the present study with heparin cofactor II, we used a comprehensive library of
HS hexasaccharide sequences built from all of the 23 disaccharide building blocks
reported to date (Figure 13B). To address the conformational variability possible in
IdoAp residues, two major ground state conformers 1C4 and 2SO, were explicitly modeled,
increasing the number of building blocks to 36 to give a library of 363 = 46,656
hexasaccharide sequences. The H/HS binding site in activated heparin cofactor II was
defined to include the domain formed by helices A and D and the polypeptide Nterminus.29
GOLD-based docking, with 10,000 iterations and 10 GA evaluations, of the
46,656 hexasaccharides was carried out to identify sequences with good HCII
recognition. Figure 14 displays the histogram of GOLD scores. The profile is Gaussian,
showing that a majority of HS sequences (83.5%) bind heparin cofactor II with average
GOLD score (30–80 units). Nearly 15.7 % of sequences bind poorly (GOLD score below
30 units), while 0.8 % hexasaccharides recognize the serpin with high GOLD scores
between 80 to 106 units. This included 2 sequences with GOLD score higher than 100
and 45 sequences with score between 90 and 100 units. In comparison to the heparin–
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antithrombin system128, these overall GOLD scores are approximately 20 to 30 units
lower suggesting that the affinity of HS hexasaccharides for heparin cofactor II may be
lower than that for pentasaccharide binding to antithrombin. We chose 47 sequences (the
top 0.1%) as candidates for the convergence (‘specificity’) test (not shown).

Start
Combinatorial Library generation
(GlcNp (4C1), GlcAp (4C1), & IdoAp (1C4 & 2SO);
Average inter-glycosidic torsions)

YES Overall Library Size?
Topologies ≥ 500?

NO

GOLD-based docking/scoring
(18 Å radius, 10 GA runs, 10,000
iterations each)

Tight Binding?
GOLDScore ≥ 99.9%
(‘specificity’ filter)

NO

YES
GOLD-based docking/scoring
(18 Å radius, 100 GA runs, 100,000 iterations each)
Consistent Binding?
RMSD ≤ 2.5Å? (‘specificity’ filter)

NO

YES

‘Nonspecific’
sequences

‘Specific’
sequences

Figure 12. Dual-filter algorithm used to screen a combinatorial library of 46,656 H/HS
hexasaccharide sequences. The hexasaccharide library was built from 36 naturally
occurring disaccharide building blocks using the average backbone model and screened
using two filters, an ‘affinity’ filter and a ‘specificity’ filter. The affinity filter
corresponded to a GOLD score in the top 0.1% or less hexasaccharide sequences, while
the specificity filter corresponded to reproducibility of binding geometries in successive
experiments to within RMSD of less than 2.5 Å. See Experimental Section for details.
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Figure 13. Structure of high-affinity heparin pentasaccharide (A) and naturally occurring
disaccharide building blocks used in the construction of combinatorial virtual library (B).
Heparin pentasaccharide DEFGH (A) binds antithrombin with high-affinity and high
specificity, yet does not recognize heparin cofactor II. Disaccharide building blocks used
in the combinatorial library construction (B) include GlcAp disaccharides on the left and
IdoAp disaccharides on the right. X represents substitution possible on the 2-position of
uronic acid residue, while Y and Z represent that on the 3- and 6-positions of the
glucosamine residue, respectively. Ten GlcAp- and 13 IdoAp-containing disaccharides
are found in nature, respectively, of which the IdoAp residue can either be 1C4 or the 2SO
form, thus giving a total of 36 disaccharide building blocks.
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Figure 14. Histogram of number of HS hexasaccharide sequences for every 10 unit
change in GOLD score. Modified GOLD score was calculated for all 46,656
hexasaccharides docked onto heparin cofactor II following the first phase of
combinatorial library screening. Inset shows an expanded portion of the histogram in the
range 90–110 GOLD score units.
Structural Features of the ‘High-Affinity’ HS Hexasaccharides
Structural analysis of the sequences identified through the ‘affinity’ filter reveals
interesting insight into recognition of heparin cofactor II. Of the 47 hexasaccharides, only
4 carry the maximal possible sulfation load of 9 groups, while the library contains a total
of 1728 sequences with the maximum load. This suggests that the majority of the highaffinity sequences are not highly sulfated. It also suggests that the GOLD fitness function
does not arbitrarily select for higher sulfation level, although the binding site in heparin
cofactor II is highly electropositive. The GOLD fitness function is driven by hydrogen
bond and van der Waals’ potential functions only, and not by Coulombic interactions,
making it particularly suited for weeding out GAG structures with low complementarity.
The 8 topologies corresponding to the common heparin hexasaccharide sequence,
[IdoAp2S-GlcNp2S6S]3, which also carry 9 sulfate groups, have GOLD scores in the
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range of –2.7 to 66.4 units, suggesting that these sequences recognize heparin cofactor II
with poor affinity. These results are consistent with solution experiments with
heterogeneous, polydisperse heparin sample that show poor heparin cofactor II affinity in
the range of 45–140 mM.143-145
The ratio of IdoAp and GlcAp containing disaccharides in our combinatorial
library was 2.6:1, while it was found to be 1.2:1 in the 47 hexasaccharides. This implies a
significant enrichment of GlcAp-residues. Additionally, the 47 identified hits do not
contain the hexasaccharide sequences related to the high-affinity pentasaccharide
(IdoAp2S [2SO/1C4]-GlcNp2S6S-GlcAp-GlcNp2S3S6S-IdoAp2S [2SO/1C4]-GlcNp2S6S),
which were found to have GOLD scores in the range of 50–54. This result is also
consistent with Maimone and Tollefsen, who have shown that heparin molecules with or
without the high-affinity antithrombin-binding pentasaccharide sequence equally activate
HCII.130
Finding Needle(s) in the Haystack: Only two HS hexasaccharides are predicted to
recognize heparin cofactor II with high-specificity.
The convergence (‘specificity’) filter used in our dual-filter algorithm is a robust strategy
to identify sequences that possess exceptional complementarity to the receptor. This filter
utilizes 3 experiments of 100 GA runs each, in which each GA run is allowed to evolve
over 100,000 iterations, resulting in 6 final binding geometries. Binding is deemed to be
specific if the RMSD among these geometries is ≤ 2.5 Å. Of the 47 sequences that were
subjected to this stringent criterion, only 2 sequences (HX1 and HX2) were found to
recognize activated heparin cofactor II with high specificity (Figure 15A).
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Several points about the structure of these two hexasaccharide sequences are
striking. None of the GlcNp residues have an acetyl group at the 2-position. This is
striking because natural heparan sulfate consists of nearly 50–60 % GlcNp2Ac
residues.146,147 The total number of sulfate groups in these sequences are 8 (HX1) and 7
(HX2). This averages to about 2 to 3 sulfate groups per disaccharide sequence. In
contrast, the degree of sulfation of human liver HS was found to be 1.2, while that of
porcine liver HS and porcine intestinal heparin was found to be 1.0 and 2.6,
respectively.146,148 Thus, these sequences are significantly more sulfated than natural HS,
but either equal to or slightly less sulfated in comparison to natural heparin. Yet, these
sequences are not heparin-like because the IdoAp composition is 0.0% whereas for
heparin, it is > 80%.122,149
Significance of Our Two Step Approach of Identifying Potential HCII-Binding HS
Sequences
The identification of the 2 “high-specificity” HS hexasaccharides is based upon
the geometry convergence of 47 top-scoring sequences that comprised 0.1 % of all
hexasaccharides in the virtual HS library. Yet, it is possible that some of the filtered
sequences from the first affinity screen may have been false negatives due to pretermination of the genetic algorithm or insufficient number of iterations (see
‘Experimental Section’). In other words, putting these filtered sequences through the
more robust, but time-consuming geometric convergence test may reveal additional
“high-affinity” sequences.
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ZbB-Yb26A-Zb2B-Yb23A-Zb2B-Yb23A

ZbB-Yb26A-ZbB-Yb23A-Zb2B-Yb26A

B
ZbB-Yb2A-Zb2B-Yb23A-ua2A-Yb2A

Figure 15. Structures of HS hexasaccharide sequences A) HX1 and HX2, which are
predicted to recognize heparin cofactor II with ‘high affinity-high specificity’ and B)
HX3 ‘high affinity’ sequence. A) Sequences HX1 and HX2 are predicted to bind HCII
with ‘high affinity-high specificity’ from the combinatorial virtual library screening.
These sequences have almost 85% of similar residues. The major difference in the
sequence is with the position of sulfation at residue C (red) and F (magenta). Each
sequence contains more than one residue that is rarely found in naturally occurring
heparan sulfate, including GlcAp2S and GlcNp2S3S. See text for details. B) Sequence
HX3 which was predicted to bind HCII with ‘high affinity’ from the critical analysis of
CVLS. But this sequence failed at the second filter (‘specificity’). This sequence had
IdoAp containing disaccharide (blue). See text for details. For naming conventions of
hexasaccharides see Appendix A.
To test if potential high-affinity HS sequences may be present in the set of HS
sequences that did not pass the affinity test, we randomly choose 47 of these sequences, 5
from each of the 10 histograms bins in Figure 14, and subject them to the geometry
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convergence test. Our results revealed that only one (HX3) of the 50 sequences passed
the test. This sequence had an IdoAp containing disaccharide (Figure 15B). Additionally,
the binding mode of this sequence is approximately 15-20° away from the ‘high
specificity’ sequences. The calculation of RMSD for this sequence (HX3) (for triplicate
runs) was >2.5Å (Figure 16A). This result suggests that our two-step docking approach
is well suited to eliminate false positives; it is unlikely that false negative solutions have
been overlooked.
Docking of ‘high specificity’ and ‘high affinity’ sequences with other serpins and
Coagulation enzymes
The 2 “high-specificity” HS hexasaccharide sequence from our dual filter algorithm and
one ‘high affinity’ sequence obtained from critical analysis of the first filter were used for
further docking with other serpins and coagulation enzymes. Since the binding site of
both HCII and AT results in a RMSD of 1.5 Å indicating a high degree of similarity
between the two native serpins, all three sequences were docked in triplicate to the crystal
structure of AT (PDB ID: 1TB6)134 which resulted in 6 solutions for each of the
sequence. The application of ‘specificity’ filter to these solutions yields an RMSD >2.5Å
for all 3 sequences (HX1to HX3) (Figure 16A). Further in order to check whether these
sequences were similar in binding to other serpins and coagulation enzymes, the same
triplicate docking was done for these 3 sequences. The molecular docking was carried out
for serpins like alpha-1-antitrypsin (α1-PI) (PDB ID: 1EZX),34 plasminogen activator
inhibitor-1(PAI1) (PDB ID: 1B3K),150 protein C inhibitor (PCI) (3DY0)151 and Protease
Nexin-1(PN1) (PDB ID: 4DY0)152 and the coagulation enzymes like thrombin (TH)
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(PDB ID: 1XMN),137 factor IXa (FIXa) (PDB ID: 3KCG),153 factor Xa(FXa) (PDB ID:
2GD4)154 and factor XIa(FXIa) (PDB ID: 2F83).102 The RMSD analysis of these docked
sequences showed that the ‘highly specific’ sequences (HX1 and HX2) of HCII were
completely non-specific in recognition to both serpins and coagulation enzymes (Figure
16). Similarly the high affinity sequence (HX3) was also found to be non-specific in
recognition. This result suggests that the sequences HX1 and HX2 are ‘highly specific’ in
HCII recognition.
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Figure 16. RMSD plot for the 3 specific sequences A) with serpins and B) with
Coagulation enzymes.
Molecular Interaction Profile of the two Predicted ‘High-Affinity, High-Specificity’
Sequences
Both the sequences bind activated HCII in an essentially identical orientation with the
non-reducing end recognizing helix A, while the reducing end is oriented toward the Cterminus of helix D (Figure 17A and Figure 18A). This suggests good specificity in the
recognition of activated HCII. In fact, a RMSD of 0.9 Å is found for backbone atoms of
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the central tetrasaccharide BCDE among the highest scoring docked solutions for each
sequence, which increases to 2.5 Å, if one considers the backbone atoms of all six
residues. Both HX1 and HX2 sequences strongly hydrogen bond to activated HCII. The
HS hexasaccharides orient at a ~60° angle relative to the axis of helix D. This alignment
is significantly different from heparin pentasaccharide binding to antithrombin, which
orients almost parallel to the axis of helix D.22,134 When both HX1 and HX2 were docked
to antithrombin they bind ~10° relative to heparin pentasaccharide sequence (Figure 17B
and Figure 18B). The hexasaccharide sequences HX1 and HX2 forms a strong hydrogen
bond with residues, Arg103, Arg184, Lys185, His188, Arg192 and Arg464 (Figure 19).
Closer inspection of interaction at the atomic level reveals that the high scoring residues –
Arg464, Arg184 and Arg192 – form multi-valent hydrogen bonds. Specifically, Arg464
forms 3 strong hydrogen bonds, two with the B2S group and one with the C2S group,
Arg184 forms 2 hydrogen bonds with the D2S and E2S groups, while Arg192 forms 1 – 2
hydrogen bonds with F3S group. Together these four sulfate groups on the GAG are
responsible for over 85% of the calculated hydrogen bonds. This analysis suggests that a
core, conserved tetrasaccharide BCDE with the minimal sequence GlcNp2S—
GlcAp2S—GlcNp2S—GlcAp2S appears to be critical for high-affinity, high-specificity
binding to activated heparin cofactor II. Additionally, sulfation at 3 positions in residue
D, introduces additional interactions with Lys185, respectively.
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Figure 17. Overlay of HX1 on HCII and AT.
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Figure 19. Interaction of HX1 with HCII
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Figure 20. Interaction of HX2 with HCII
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3.2.2. Synthesis of the Hexasaccharides
The hexasaccharides (HX1-HX3) were synthesized by the Oscarson lab at UCD School
of Chemistry and Chemical Biology, University College of Dublin, Ireland.
3.2.3. Hexasaccharides Bind to HCII and AT With Good Affinity
To put the computational predictions to test, we studied the interaction of the designed
hexasaccharides with HCII and AT utilizing intrinsic tryptophan fluorescence
spectroscopy, as reported in literature.155,156 All three hexasaccharides demonstrated a
characteristic saturable change in fluorescence emission at 340 nm (λEX = 280 nm) under
pH 7.4, I 0.06, 25 ºC conditions indicative of good interaction (Figure 21). Whereas a
decrease in fluorescence was observed for each hexasaccharide binding to HCII (-26 to 33%), an increase was noted for AT (32 to 46%). Although the changes for the two
related serpins are dramatically distinct, these are in line with those reported in the
literature for other oligosaccharides.14 Also, heparin pentasaccharide H5 also shows
equivalent order of changes (-24% and 32%, respectively, Table 6). The affinities for
HCII derived from the fluorescence profiles were calculated to be in the range of 29 to 45
µM for the three HXs. These compare favorably to the HCII affinities reported for high
affinity hexasaccharide sequences extracted from UFH and DS (20-40 µM).92,130
Interestingly, H5 was found to bind with an affinity of 9.2 µM, which was better than the
HXs. In comparison to HCII, the HXs bound antithrombin with much more varied
affinities. HX1 and HX2, the two primary hexasaccharide sequences targeted by
computational design, displayed affinities of 7.9 and 49 µM, while HX3 interacted with a
KD of 75.3 µM (Figure 20, Table 6). These affinities are much weaker than the low nM
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affinity noted for H5 in the literature.14,57
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Figure 21. Affinity of hexasaccharides HX1–HX3 for antithrombin (A) and heparin
cofactor II (B) in 20 mM sodium phosphate buffer, pH 7.4, containing 25 mM NaCl at 25
°C. The affinity was measured from the proportional change in fluorescence emission
(ΔF/F0) at 340 nm (λEX = 280 nm) as a function of the concentration of the HX, which
was fitted using quadratic eq 1 (solid line) to derive the maximal fluorescence change
(DFMAX) and equilibrium dissociation constant (KD). See ‘Experimental Section’ for
additional details.
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Table 6: Equilibrium dissociation constant (KD) and maximal fluorescence change
(DFMAX) for hexasaccharide–serpin complexes.a
AT

HCII

KD

ΔFMAX

KD

ΔFMAX

(mM)

(%)

(mM)

(%)

HX1

7.9±0.5b

32±4

29.4±6.9

-33±5

HX2

48.7±8.7

46±4

17.6±4.0

-26±3

HX3

75.3±5.9c

45±4

44.5±3.8

-32±2

0.05±0.006c

32±3

9.2±1.2

-24±1

H5
a

Measured using intrinsic (Trp) fluorescence in 20 mM sodium phosphate buffer, pH 7.4,
containing 25 mM NaCl, at 25 °C. See Materials and Methods for additional details.
b
Error represents ±1 S.E. cTaken from Desai et al.5
3.2.4. Hexasaccharides Activate Serpin Inhibition of Target Protease
To assess the influence of HXs on the ability of serpins to inhibit their target protease, we
studied the kinetics of HCII inhibition of TH and AT inhibition of FXa in a discontinuous
assay at pH 7.4, I 0.06, 25 ºC, as described earlier.93 The exponential decrease in residual
protease activity as a function of time was used to derive the observed pseudo-first order
rate constant (kOBS) (Figure 22). The kOBS of inhibition was found to increase linearly
with the concentration of HX–serpin complex, which was used to obtain the second-order
rate constant for the uncatalyzed inhibition (kUNCAT) from the intercept and HX-catalyzed
inhibition from the slope (kHX) (Table 7).
The kUNCAT for HCII–TH system and AT–fXa system was found to be 1.1–1.3
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×103 M-1s-1 and 2.2–2.4×103 M-1s-1, respectively (Table 7). These values compare
favorably with basal rates reported in the literature.14,93 The kHX for HCII–TH reaction in
the presence of HX1 was measured to be 2.4×105 M-1s-1, which implies an acceleration of
~208-fold. HX2 and HX3 displayed an acceleration of ~43- and 71-fold, respectively.
Likewise, heparin pentasaccharide H5 was found to induce a 49-fold acceleration in
HCII–TH reaction. With regard to AT inhibition of FXa, HX1 and HX2 revealed
accelerations of ~346- and ~380-fold, respectively, while HX3 displayed a weaker
acceleration of ~63-fold (Table 7, Figure 22). In comparison, H5, a clinically used
anticoagulant targeting the AT – fXa system, displays accelerations in the range of 275 –
300-fold.14
To assess whether the observed accelerations arise from direct interaction of the
proteases by HXs, we performed inhibition studies in the absence of the respective
serpins. Using chromogenic substrate hydrolysis assay, the residual protease activities
were monitored at HX concentrations as high as 500 µM against both TH and FXa. No
inhibition of either enzyme was noted in these studies (not shown) suggesting that the
HXs function only through an indirect mechanism of action. Overall, HXs were found to
significantly affect serpin inhibition of target proteases. HX1 was found to
simultaneously induce robust acceleration of both AT and HCII against their preferred
targets, as predicted on the basis of computational design.
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Figure 22. Kinetics of serpin inhibition of target protease in the presence of
hexasaccharides HX1–HX3 in 20 mM sodium phosphate buffer, pH 7.4, containing 25
mM NaCl at 25 °C. The residual TH activity (A, B and C) or FXa activity (D, E and F)
was measured from the initial rate of substrate hydrolysis under pseudo-first-order
conditions as a function of time in the presence of HX1 (A and D), HX2 (B and E) and
HX3 (C and F) and fixed concentrations of HCII (A, B and C) or AT (D, E and F). Panel
G and H shows the profile of the observed pseudo-first order rate constant of HCII (G) or
AT (H) inhibition (kOBS) at different HX concentrations and its analysis using linear
equation 2 (solid lines) to obtain the uncatalyzed (kUNCAT) and catalyzed (kHX) rate
constants. See ‘Experimental Section’ for additional details.
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Table 7: Acceleration in serpin inhibition of coagulation enzymes brought about
by HX.a
AT-FXa
kUNCAT

kHX

(M-1s-1)

(M-1s-1)

HX1

2.4±0.2×103c

8.3±0.3×105

HX2

2.1±0.5×103

HX3
H5d

HCII-TH
Activationb

Activationb

kUNCAT

kHX

(M-1s-1)

(M-1s-1)

346±41

1.1±0.2×103

2.4±0.1×105

208±48

8.0±0.5×105

381±114

1.2±0.3×103

5.1±0.2×104

42.7±12.4

2.2±0.3×103

1.4±0.1×105

62.4±7.0

1.3±0.3×103

8.8±0.2×104

70.5±16.7

2.3±0.1×103

6.1±0.3×105

275±25

1.4±0.2×103

6.8±0.4×104

49.0±17

a

Measured using discontinuous enzyme inhibition assay in 20 mM sodium phosphate
buffer, pH 7.4, containing 25 mM NaCl, at 25 °C. See Experimental Methods for
additional details. bRefers to the ratio of catalyzed and uncatalyzed rate constants. cError
represents ±1 S.E. cTaken from Lindahl et al.6
3.2.5. Hexasaccharides are Potent Anticoagulants in Human Plasma
To assess if the promising activation of HCII and AT against TH and fXa, respectively,
translates into promising anticoagulation potential in human plasma, we utilized the
activated thromboplastin time (APTT). The ability of the HXs to prolong clotting was
quantified in the form of the concentration required to double the clotting time (Figure
23). A HX1 concentration of 85 µM doubled APTT, while 323 and 824 µM levels were
needed for HX2 and HX3 (Figure 23). In comparison, 34 µM H5 was minimally needed
for 2×APTT. This implies that HX1 and H5 are approximately equipotent in this human
plasma anticoagulation test, while other two HXs are much less potent. A plausible
explanation for this difference is the higher affinity of H5 and HX1 for the two serpins in
comparison to the other HXs. Interestingly, the observed 85 µM 2×APTT for HX1 is
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only about 10 and 3-fold lower than its affinity for AT and HCII, respectively. In
contrast, H5 demonstrates a loss of ~6800 and 3.7-fold, respectively.
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Figure 23. Pooled human plasma clotting time at varying levels of hexasaccharides
HX1–HX3 and heparin pentasaccharide H5 measured using the APTT assay. Solid lines
are trend lines, which were used to calculate the concentration required to double the
clotting time.
3.3. DISCUSSION
3.3.1. Designing Hexasaccharides Targeting HCII.
The heterogeneity and the non-specific heparin-based interaction were thwarted by the
advent of a more specific pentasaccharide sequence identified for AT. The first total
synthesis of the pentasaccharide in low yields laid the foundation to achieve a degree of
understanding to this otherwise unknown interaction.131 We have utilized a computational
based approach to identify a similar specificity for the closely related serpin HCII. Three
hexasaccharides were synthesized to test our hypothesis, which included HX1 and HX2
as molecules specific for HCII and, HX3 predicted to be non-specific. Structurally, each
of these possesses an alternating uronic acid and glucosamine units, sulfated strategically
to unearth specific interactions with HCII identified computationally (Figure 19 and 20).
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HX1 and HX2 are identical with minor changes at the B residue 2-position sulfate and
the F residue 3-position sulfate (Figure 24). Comparatively, H5 possess an iduronic acid
at the G residue, replaced by a glucuronic acid for HX1 and HX2 (residue E). However,
HX3 does retain the iduronic acid at the same residue but lacks the important 6-OSO3−
groups at the D residue (Figure 24) These hexasaccharides do possess an extra glucuronic
acid residue in comparison to H5. The basis of these structural modifications are derived
through our computational strategy and its translation into actual measured activity
(Table 7) does indicate the robustness of our strategy.
3.3.2. Reported Structural Studies for the AT-FXa system
AT is a major regulator in maintaining normal hemostasis. It achieves this by targeting
major coagulation proteases like FXa, thrombin and FIXa.15 Heparin was the first known
activator of AT but, is highly non-specific due to its large anionic and heterogenous
character. Reducing its overall size and anionic character produced a striking
improvement in specificity showcased by the small and specific heparin pentasaccharide
(DEFGH, Figure 24).132,157,158 Additionally, the improved specificity reduces the
possibilities

of

non-specific

interactions

with

other

proteins.159

The

natural

pentasaccharide was further studied through the synthesis of a plethora of synthetic
variants.16,17,132,133 Each of these extensive libraries has helped advance more potent and
stable variants (Table 8). Important structural data established from these studies indicate
that the 6-position of residue D, 3- and 2-position of residue F, and 2-position of residue
H, are crucial for binding to antithrombin (Figure 24). Further synthetic derivatives
revealed the replacement of the NHSO3− group in all three glucosamine residues with
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OSO3− and the addition of alkyl ethers at the free hydroxyl groups produce an
enhancement of activity132 (DEFGH-NGA, Table 8). Additionally, altering the backbone
O-glycosidic bond with a C-glycosidic bond did not affect the activity (C-DEFGH,
Table 8).45 Similarly, the addition of a hydrophobic unit (95, Table 8) did not alter
activity.133 The AT-H5 system is a well-studied system and extending this to the HCIITH system has been widely pursued.
Table 8: List of natural pentasaccharide and its derivatives.a
DEFGH derivatives
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Pentasaccharide derivatives as antithrombin based anticoagulant. Red refers to the
residues known to be important in the pentasaccharide sequence and blue refers to the
changes incorporated in comparison to the original DEFGH pentasaccharide sequence
found in heparin.bCompiled from van Boeckel and Petitou160 and Petitou et al.45
3.3.3. Reported Structural Studies for the HCII-TH system
HCII has evolved to be an adjunct to AT in regulating the circulatory levels of thrombin.
Unlike AT, HCII only targets thrombin, affecting both the clot bond and the free form of
thrombin.145 Its adjunct role postulated to be more essential in pathophysiological
responses, has resulted in a flurry of research aimed at developing agents targeting this
system. Literature reports include the polymeric saccharide based effectors like dermatan
sulfate, heparin and heparan sulfate,161 chitosan polysulfate,162 fucoidan,163 fucosylated
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chondroitin sulfate164 shown to produce a drastic acceleration of HCII for thrombin
inhibition. The polymeric structure of these however, incorporates numerous
complexities in terms of their structure and purity, making it almost impossible to
reproducibly use these in a clinical setting. Thus the impetus to identify smaller, well
characterized effectors.
In an attempt to replicate the high affinity heparin pentasaccharide in the HCII system,
the polymeric mix of dermatan sulfate and heparin were successfully reduced in two
different studies to a hexasaccharide as a minimal effective unit for HCII.92,130 These
were elucidated as shown in Figure 25 indicating the structure of the heparin-based
hexasaccharide and the dermatan sulphate-based hexasaccharide. Reports suggest the
hexasaccharide comprises ~5% of disaccharides present in dermatan sulfate. This has
been reportedly synthesized.165 Similarly, studies with the heparin-based hexasaccharide
indicates a dual interaction and acceleration of HCII in addition to potentiation of AT
mediated inhibition of FXa, a feature indicated in the HXs studied here. Numerous
reports incorporating depolymerization strategies have identified hexasaccharides based
effectors,22,166,167 however the maximum activity afforded by these has been ~100-fold,
moderate in comparison to the ~2000-fold observed for heparin and dermatan sulfate.92
Non-saccharide based sucrose octasulfate specifically activates HCII with a 2000-fold
activation, however its affinity for HCII is poor at 1.45±0.30 mM. Conversely,
contrasting reports indicate it to be a direct potent inhibitor of thrombin with an IC50 of
4.5±1.1 µM, albeit with an efficacy of less than 10%.168
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3.3.4. Hexasaccharides Predictably Interact with AT
The hexasaccharide sequences studied herein, produced a potent activation of AT
comparable to DEFGH especially HX1 and HX2, with HX3 inducing a poor 63-fold
activation. Structurally, HX1 and HX2 are similar to the pentasaccharide sequence
DEFGH, the major difference being the replacement of the iduronic acid at residue G
with a gluocuronic acid (residue E) (Figure 14). The structural change does not affect the
acceleration however, could conversely affect the affinity denoted by the moderate
affinity observed in comparison to H5 (Table 6). Minor structural changes include the
addition of sulfates at the 2-position of C residue and the 4-position of the F residue
(Figure 24), both of which are not studied to be vital for activity. Predictably, HX3 which
lacks the essential sulfate group at the 6-position (Figure 24) of the B (D in
pentasaccharide) residue produces a loss in acceleration and affinity, despite of this
derivative possessing an iduronic acid at the E residue.
3.3.5. Identification of Hexasaccharide based Potent Activator of HCII
The computationally designed hexasaccharides we studied, possess a moderate affinity
for HCII, however comparable to that reported for similar hexasaccharides.92,167 The
activation profile for these indicated a high 208-fold acceleration induced by HX1, albeit
without any direct inhibition of thrombin. In comparison, to the well-studied AT-H5
system, little is known about the features required to induce specificity towards HCII.
However, a comparison to the reported heparin hexasaccharides (Figure 25) does indicate
a structural dependence to the improvement in acceleration. The reported sequence
ABCDEF (Figure 25) is essentially similar to the HXs studied, with minor changes
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including the replacement of the iduronic acid at residues A and C by a glucuronic acid in
HXs, additionally the glucuronic acid in residue E has been replaced by a iduronic acid in
HX3. The effects of these changes does indicate the importance of the sulfate at the 2position on each residue, especially the residue C with the addition of a sulfate group
increasing acceleration quantified by lack of a sulfate in HX2, producing a decrease in
acceleration. Whereas, modification in the saccharide backbone does not affect the
acceleration with both glucuronic or iduronic acid tolerated (Figure 15). Consequently,
the identification of HX1 could serve as the initial step towards developing more potent
and selective agents to target HCII more specifically.
3.3.6. Utilization in Arterial/venous Thrombosis Models
AT conventionally targets venous thrombosis through the activation of thrombin and
FXa. However, HCII possess a peculiar characteristic of specifically targeting clot bound
thrombin and could therefore be utilized in an arterial thrombosis model. HX1 possess an
activation potential for both AT and HCII and could therefore be utilized as a newer
agent in the unexplored field of dual agents, targeting both venous and arterial
thrombosis. Similarly, the affinity these possess for AT is considerably lower than that
reported for the heparin pentasaccharide (50 nM). The same affinity, which induces
specificity, is responsible for the bleeding complications reported with the use of the
heparin pentasaccharide. However, the HXs have a reportedly lower affinity for AT and
could therefore induce a measured anticoagulant effect thereby reducing the risks of
bleeding complications.
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Figure 24. Structural comparison of the DEFGH sequence and the HXs synthesized.
Blue refers to the residues deemed important as per reported studies. Red refers to the
residues altered in the HXs in comparison to DEFGH.
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Figure 25. The structure of the reported dermatan sulfate and heparin-based
hexasaccharide sequences and the comparison of the HXs and the heparin based
hexasaccharide sequence. Red refers to the backbone saccharide units altered in
comparison to the heparin-based hexasaccharide ABCDEF.
The interaction of heparin/heparan sulfate (H/HS) with heparin cofactor II was
commonly assumed to be non-specific,130,144,161 primarily because the GAG chains could
not be separated into individual high and low affinity fractions. This also poses major
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difficulties in structure elucidation since crystallization of a complex using the highly
heterogeneous, polydisperse GAG is nearly impossible. Our work suggests that there
exist at least two hexasaccharide sequences that are predicted to recognize activated
heparin cofactor II with high-affinity and high specificity. Both sequences contain at least
two GAG monosaccharides of the GlcNp2S3S or GlcAp2S type that are rare in natural
preparations of H/HS.
The fact that each sequence has at least two such rare monosaccharides suggest a
rapidly diminishing probability of finding these structures naturally. Yet, the
hexasaccharides are expected to be accessible through chemical synthesis,169 which may
catalyze interest in clarifying the mechanism of H/HS activation of heparin cofactor II as
well as advance the concept of designing potent heparin cofactor II agonists as specific
inhibitors of thrombin. Considering that the structure of H/HS–HCII complex is not
available, our combinatorial virtual library screening results have far reaching
implications.
Our dual-filter algorithm appears to be a powerful tool for deciphering specificity
of binding. For GAG-protein pairs that are difficult to study through NMR spectroscopy
and X-ray crystallography, our virtual approach provides an avenue for gaining initial
insight into ligand – protein interactions.
3.4. Experimental Methods
3.4.1. Computational Methods
Software. SYBYLX v2.0 (Tripos Associates, St. Louis, MO) was used for
molecular visualization, minimization and for preparation of protein structures from the
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Protein Data Bank (www.rcsb.org/pdb). GOLD, v5.1170 was used for molecular docking
experiments. GAG sequences were built combinatorially in an automated manner using
in-house SPL (SYBYL Programming Language) scripts.
Protein preparation. The coordinates for the activated form of heparin cofactor II were
extracted from the crystal structure of the S195A thrombin-HCII Michaelis complex
(PDB entry 1JMO).29 For comparative purposes, the co-ordinates of heparin
pentasaccharide – antithrombin co-complex were extracted from protein databank file
1TB6.134 Protein preparation was performed using the “prepare protein” module in
SYBYLX, v2.0 and included removal of water molecules, adjustment of the protonation
states of amino acid residues to physiological conditions, addition of hydrogen atoms and
the structure was minimized with fixed heavy-atom co-ordinates using the Tripos Force
Field for 1,000 iterations subject to a termination gradient of 0.05 kcal/(mol-Å).
Co-ordinates for HS Virtual Library. The co-ordinates for HS hexasaccharide
sequences present in the combinatorial virtual library were generated using a series of
SPL scripts and HS disaccharide building blocks. Although the total number of possible
disaccharides (UAp(1!4)GlcNp) is 48, only 23 have been experimentally observed
(Figure 13B).124 Of these 23, 13 disaccharides contain IdoAp, while 10 contain GlcAp
residue. Because IdoAp residue in HS can exist either in the

2

SO or

1

C4

conformations,126,171 each IdoAp-containing disaccharide was modeled explicitly in these
two different states. Thus, our virtual library consisted of 26 IdoAp and 10 GlcAp
disaccharide building blocks generating a total of 46,656 (36 х 36 х 36) hexasaccharide
sequences.

76

Each H/HS sequence within these libraries were denoted using the GLYCAM
force field172 symbols or letters for base monosaccharides (GlcNp, IdoAp and GlcAp)
and further modified by the substituents (–H, –SO3-, or –COCH3, see Appendix A).
Appropriate side-chain modifications were made to generate the 36 building blocks. Each
disaccharide was minimized using glycosidic bond torsion constraints (restraining force
constant = 0.01 kcal·mol-1·deg-2). Analysis of the available crystal structures showed that
the inter-glycosidic torsions φH (O5-C1-O1-C4’) and ψH (C1-O1-C4’-C5’) fall within a
relatively narrow range and are essentially invariant irrespective of the substitution
pattern.22,154,173,174 Thus, average bond torsions (see Appendix B), were used for interglycosidic linkages. The 36 disaccharides were then used to build a combinatorial HS
hexasaccharide library using an SPL script in an automated manner, following which
each sequence was again minimized using glycosidic bond torsion constraints to generate
HS sequences with ‘average backbone’ geometries.91,128
Docking of the Comprehensive HS Virtual Sequence Library.
Docking of HS ligand onto the activated form of heparin cofactor II was
performed with GOLD v5.1. GOLD is a "soft docking" method that implicitly handles
local protein flexibility by allowing a small degree of interpenetration, or van der Waals
overlap, of the ligand and protein atoms.170 GOLD also optimizes the positions of
hydrogen-bond donating atoms on Ser, Thr, Tyr, Lys, and Arg residues as part of the
docking process. GOLD starts with a population of 100 arbitrarily docked ligand
orientations, evaluates them using a scoring function (the GA “fitness” function) and
improves their average “fitness” by an iterative optimization procedure that is biased
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towards high scores. Docking was driven by !"#$%&'() = !"!"# + 1.375×!"#!"#
equation (HBEXT and VDWEXT are the non-bonded intermolecular hydrogen bond and van
der Waals terms, respectively) to prioritize different poses, as reported earlier
(Raghuraman et al. 2006). As the initial population is selected at random, several such
GA runs are required to more reliably predict correct bound conformations. In our study
10 GA runs were used, which are collectively referred to as one docking experiment.
Evaluation of the HS combinatorial library was performed using a two-stage
docking protocol (Figure 12), as utilized in our study of the antithrombin-heparin
pentasaccharide system.128 The first stage (the ‘affinity’ test) involved docking of 46656
HS sequences to HCII to efficiently identify sequences with high affinity for the binding
site. To enhance the speed of the search, all sequences were docked using 10,000
iterations (7 – 8X speed up setting) per GA run. Additionally, the GA was set to
terminate early if, during the course of docking, the top two ranked solutions were within
2.5 Å RMSD.
For the overall top-ranked docked solution for each of the HS sequences, a
modified GOLD score was calculated. Although the GOLD fitness function generally
correlates with the observed free energy of binding, a modified form has been found to be
more reliable.175 This modified GOLD score utilizes only the “external” hydrogenbonding and van der Waals terms of the GOLD fitness function (above equation). The
GOLD score, as it is reported in this paper, refers to this modified GOLD scoring
function. The top solutions were re-ranked based on the GOLD score, and the top 0.1%
were selected for the convergence (‘specificity’) test.
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The ‘specificity’ test consisted of docking the most promising HS sequences from
the ‘affinity’ test using the standard GOLD parameter settings (no speed-up; 100,000 GA
iterations). The top two solutions of each docking experiment were considered for further
analysis. Docking was performed in triplicate to yield a minimum of 6 solutions. A
RMSD of less than 2.5 Å among the backbone heavy atoms (pyranose ring atoms and
interglycosidic oxygens) of all 6 solutions suggested a high degree of convergence to a
‘unique’ binding geometry. These HS sequences were deemed to be specific.
In both the first and second docking stages, the binding site in heparin cofactor II
was comprised of all atoms within 18 Å from the C atom of Lys185 in the D helix. This
γ

dimension of the binding site covers a number of basic residues including Lys101,
Arg103, Lys173, Arg184, Lys185, Arg189, Arg192, Arg193, Lys220, and Arg464, which
are present in the putative heparin-binding domain formed by helices A and D, and part
of the N-terminus.
3.4.2. Proteins and Chemicals
Human plasma antithrombin (AT), heparin cofactor II (HCII), human thrombin (TH) and
human factor Xa (FXa) were purchased from Haematologic Technologies (Essex
Junction, VT). AT, HCII, thrombin and FXa were stored in 20 mM sodium phosphate
buffer, pH 7.4, containing 25 mM NaCl, 0.1 mM EDTA and 0.1% (w/v) PEG8000 at -20
°C. Spectrozyme FXa (methoxycarbonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide)
and Spectrozyme TH (H-D-hexahydrotyrosol-Ala-Arg-p-nitroanilide) were obtained
from American Diagnostics (Greenwich, CT) and prepared in 20 mM sodium phosphate
buffer, pH 7.4, containing 25 mM NaCl, 0.1 mM EDTA and 0.1% (w/v) PEG 8000.
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Pooled normal human plasma for coagulation assays was purchased from Affinity
Biological (Ancaster, Ontario). Activated partial thromboplastin time reagent containing
ellagic acid and 25 mM CaCl2 were obtained from Fisher Diagnostics (Middletown, VA).
3.4.3. Equilibrium Binding Studies using Fluorescence Spectroscopy
The equilibrium dissociation constants of hexasaccharide (HX) – protein complexes were
measured using change in fluorescence emission as a function of the concentration of the
hexasaccharides in 20 mM sodium phosphate buffer, pH 7.4, containing 25 mM NaCl,
0.1 mM EDTA and 0.1% PEG8000 at 25 °C, as described earlier.14,156 The experiments
were performed using a QM4 fluorometer (Photon Technology International,
Birmingham, NJ) in a quartz microcuvette by titrating a 200 µL solution of the protein
(100–200 nM) and monitoring the change in the fluorescence at 340 nm (λEX = 280 nm).
Excitation and emission slit width were set to 1.0 mm for each experiment. The saturable
change in fluorescence signal was fitted using the quadratic equilibrium binding eq 1 to
obtain the KD of interaction. In this equation, ΔF represents the change in fluorescence at
a fixed concentration of HX from the initial fluorescence F0 and ΔFMAX represents the
maximal change in fluorescence following saturation of the protein. [P]0 represents the
total concentration of either AT or HCII.
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3.4.4. Kinetics of Protease Inhibition in the Presence of HX
The kinetics of inhibition of coagulation proteases TH or FXa by AT or HCII in the
presence of HX was measured spectrophotometrically using a microplate reader
(FlexStation III, Molecular Devices) under pseudo-first-order conditions, as described
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earlier.82,176 Briefly, a fixed concentration of TH or FXa (~5 nM) was incubated with
fixed concentrations of plasma AT or HCII (100 nM) and hexasaccharides (0 – 3200 nM)
for HX1, (0 – 22 mM) for HX2 and (0 – 10 mM) for HX3 in 20 mM sodium phosphate
buffer, pH 7.4, containing 25 mM NaCl, 0.1 mM EDTA and 0.1% (w/v) PEG 8000 at 25
°C. At regular time intervals, an aliquot of the inhibition reaction was quenched with 100
µL of 125–200 µM chromogenic substrate (Spectrozyme TH or Spectrozyme FXa) in 20
mM sodium phosphate buffer, pH 7.4, containing 25 mM NaCl at 25 °C. To determine
the residual protease activity, the initial rate of substrate hydrolysis was measured from
the increase in absorbance at 405 nm. The exponential decrease in the initial rate of
substrate hydrolysis as a function of time was used to determine the observed pseudofirst-order rate constant of protease inhibition (kOBS). A plot of kOBS at different
concentrations of HX–serpin complex could be described by eq 2, in which kUNCAT is the
second-order rate constant of protease inhibition by serpin alone and kHS is the secondorder rate constant of protein inhibition by serpin-HX complex (HX:P).
!!"# = ! !!"#$% [!]! + ! !!" ![!": !]

(2)

3.4.5. Direct Protease Inhibition in the Presence of HX
Direct inhibition of TH or FXa by hexasaccharides was assessed through a chromogenic
substrate hydrolysis assay using a microplate reader (FlexStation III, Molecular Devices),
as described earlier.177 Briefly, each well of the 96-well microplate contained (190–X) µL
of the pH 7.4 buffer to which X µL of HX (to give a 500 µM final concentration), or an
appropriate reference, was added followed by 5 µL of protease (to give 5 nM final
concentration). After 10 min incubation at 25 °C, 5 µL of appropriate chromogenic
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substrate (to give 125 mM (Spectrozyme FXa) or 100 mM Spectrozyme TH) was rapidly
added and the residual protease activity was measured from the initial rate of increase in
A405. Relative residual protease activity at each concentration of HX was calculated from
the ratio of the activity in the presence and absence of the inhibitor.
3.4.6. Activated Partial Thromboplastin Time (APTT)
Clotting time was measured in a standard one-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton−Dickinson, Sparles, MD). In the APTT assay, X µL of
oligosaccharides (H5 and HX) were mixed with (100 – X) µL of citrated human plasma
and 100 µL of prewarmed APTT reagent (0.2% ellagic acid). After incubation for 4 min
at 37 °C, clotting was initiated by adding 100 µL of prewarmed 25 mM CaCl2 and the
time to clot was noted. The data were fit using a quadratic trend line, from which the
concentration of the oligosaccharides (H5 and HX) necessary to double the clotting time
was calculated. Clotting time in the absence of an anticoagulant was determined in a
similar fashion using 10 µL of deionized water and was found to be 32.1 s on an average
for APTT.
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CHAPTER 4: DIFFERENTIAL RECOGNITION OF COAGULATION
PROTEINS BY HEPARAN SULFATE CONTAINING 2-O-SULFATED
GLUCURONIC ACID
4.1 Introduction
Sulfated glycosaminoglycans (GAGs), natural linear co-polymers of hexuronic
acid and hexosamine residues, represent nature’s bounty of chemical biology tools. Yet,
the current state-of-art displays minimal exploitation of this promise. Few GAG-based
therapeutic agents have been discovered other than naturally occurring heparin, dermatan
sulfate and chondroitin sulfate. A major challenge in realizing the pharmacologic
potential of GAGs is the structural diversity inherent in every natural GAG preparation.
The variations introduced by incomplete sulfation, deacetylation, and epimerization
reactions during their biosynthesis,124,178-180 coupled with postsynthetic fine tuning of
GAG structure by sulfatases,181 generates millions of distinct sequences that defy
resolution and analysis at high homogeneity levels.
Despite this challenge, sulfated GAGs are attractive. The presence of sulfate
(%OSO3¯) groups on a GAG chain induces recognition and modulation of most proteins,
especially those that display a collection of Arg/Lys residues on their surface. This gives
rise to GAG modulation of a large number of physiological and pathological responses
such as growth and cancer, cell renewal and differentiation, hemostasis and fibrinolysis,
inflammation and immune response, and microbial invasion and defense.120,124,182-185 It is
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likely that individual proteins bind to only a subset of GAG sequences from the natural
repertoire of millions. A classic example of this high selectivity is the heparin
pentasaccharide sequence, containing a rare 3-O-sulfate glucosamine (GlcNp) residue,
which binds to antithrombin (AT), a serpin involved in regulation of hemostasis and
coagulation, with an affinity of ~50 nM.14 Another example suggested in the literature is
that of a dermatan sulfate hexasaccharide that binds heparin cofactor II (HCII), another
plasma serpin, with high selectivity and an affinity of 20 µM.92 Although both AT and
HCII possess considerable three-dimensional similarity,186 they prefer completely
different GAG sequences.91 Thus, the possibility is high that distinct GAG sequences
may modulate proteins in a selective manner.
How can such distinct GAG sequences be identified and studied as chemical
biology tools? An often utilized approach is computational study of individual GAG–
protein interactions.187 Examples of such studies include the prediction of GAG binding
sites on enzymes (e.g., cathepsin S188 and heparanase189), enzyme inhibitors (e.g.,
antithrombin,128 heparin cofactor II91 and alpha-1-proteinase inhibitor190),. membrane or
cell surface proteins (e.g., αvβ3 integrin,191 growth factor receptor192 and human
papillomavirus major capsid protein L1),193 cellular or extracellular proteins (e.g., bone
morphogenetic proteins194 and growth factors),195,196 and matrix proteins (e.g.,
thrombospondin-1).197 Despite this voluminous effort, the number of GAG sequences that
exhibit selective targeting of proteins has remained low.
We reasoned that a simple approach to identify selective GAG sequences is to
consider rare sequences. Sequences that are rarely present in natural GAGs are most
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probably biosynthesized for a specific reason and likely to exhibit selective modulation of
target proteins, as exemplified by the 3-O-sulfated GlcNp residue.14,128 In addition to its
presence in the high affinity AT binding heparin pentasaccharide, it is also part of the
heparin octasaccharide that binds glycoprotein D of the herpes simplex virus.198 No other
rare GAG residue has been discovered to date as equally interesting from the chemical
biology perspective.
A rare GAG residue of significance could be 2-O-sulfated glucuronic acid
(GlcAp2S). This residue can be biosynthesized by the action of 2-O-sulfotransferase
(2OST) on GlcAp, present in a growing heparan sulfate (HS) chain, that has escaped
epimerization reaction with the C-5 epimerase (C5E).178,199,200 Under normal biosynthetic
conditions, the growing HS chain acted upon by N-deacetylase/N-sulfotransferase
(NDST) to produce GlcNp2S and GlcAp containing sequences, majority of which are
further modified to IdoAp by C5E.149,178 2OST then acts upon IdoAp to produce
IdoAp2S, which eventually gives the most common disaccharide sequence,
IdoAp2S(1→4)GlcNp2S6S, in heparin.201 Once in a while, C5E could skip epimerization
of GlcAp resulting in the formation of a rare GlcAp2S following 2OST action.199,200
This begged the question: What biological consequences would ensue if the
GlcAp2S residue was more abundant? We used a genetic algorithm-based computational
approach to study GlcAp2S containing hexasaccharides binding to AT and discovered
elements of highly selective recognition. The HS polymer labeled as HS2S2S and
containing only GlcAp2S and GlcNp2S residues was prepared using recombinant
biosynthetic enzymes and found to potently bind and activate AT for inhibition of factor
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Xa. In addition, HS2S2S targets HCII and thrombin, but not factor Xa, which is
corroborated by computational modeling studies. The results convey the potential of
HS2S2S in understanding differential recognition of proteins of the coagulation cascade,
while also highlighting the significance of studying distinct GAG sequences for
pharmacological purposes.
4.2 Results
4.2.1 Rationale for Studying HS sequences containing GlcAp2S
As discussed above, the GlcAp2S residue is rare in natural HS.199,202 Yet, it is enhanced
2–3-fold in the cerebral cortex as compared to other tissues suggesting the possibility of
its role in an as-yet-undetermined physiologic process.200 Surprisingly, GlcAp2S is
biosynthesized by the same enzyme that generates IdoAp2S, the predominant uronic acid
of heparin, and only one isoform of this critical enzyme, 2-O-sulfotransferase (2OST),
has been identified to date, which implies that regulation of HS fine structure containing
GlcAp2S is likely to be an exquisitely fine-tuned process. Additionally, a 3-Osulfotranferase isoform (3OST-2) appears to demonstrate selectivity for sequences
containing GlcAp2S.203 This 3OST isoform is expressed more in the brain,204 which is
also the place where GlcAp2S proportion is higher.200
Apart from the biosynthesis, distribution and possible physiologic relevance
perspective, GlcAp2S residue is also attractive in the context of HS structure. A HS chain
containing GlcAp2S can be easily synthesized in only two steps. Treatment of the E. coli
K5 capsular polysaccharide with N-deacetylase/N-sulfotransferase (NDST) followed by
2OST treatment gives a HS preparation enriched in →4)GlcAp2S(1→4)GlcNp2S(1→,
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which retains the heterogeneity of HS, albeit at a lower level, because of incomplete
reactions with NDST and 2OST. This disaccharide sequence, and its counterpart
→4)GlcNp2S(1→4)GlcAp2S(1→, display significantly different electrostatic and
hydrophobic surfaces in comparison to that observed for naturally occurring H/HS
disaccharides. Nearly 50% of naturally occurring disaccharides possess a higher polar
surface area than HS2S2S (Figure 26A). 76.3% of the AT binding heparin
pentasaccharide’s solvent accessible surface area is polar, which is comparable to
HS2S2S’s 75.3%. However, the pentasaccharide displays almost 7 negative charges per
1000 Å2 in comparison to 4.6 for the HS2S2S disaccharide (Figure 26B), giving it a
significantly higher charge density. Thus, HS2S2S possesses distinct topological
characteristics when compared to the known bioactive HS pentasaccharide sequence. We
have previously reported small molecule GAG mimics that target hydrophobic sites on
the HBS of antithrombin, thrombin and factor XIa.82,103,177,205-207 We hypothesized that
HS2S2S’s distinct topology may also allow similar hydrophobic interactions with
antithrombin’s HBS.
4.2.2 HS containing GlcAp2S and GlcNp2S may Exhibit Promising AT Targeting
Capability
To assess whether GlcAp2S and GlcNp2S residues introduce novel protein recognition
features, we utilized a computational workflow that helps sort ‘specific’ and ‘nonspecific’
GAG interactions.91,128 The workflow involved a ‘steady state with no duplicates’ genetic
algorithm (GA) to place HS2S2S sequence containing hexasaccharides onto the heparinbinding site (HBS) of AT. A GA is an artificial intelligence program that explores the 3-
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dimensional space around a binding site and attempts to find optimal position(s) for a
ligand through an iterative process of natural selection, or alternately ‘survival-of-thefittest’ rules. For studying the library of HS2S2S hexasaccharides binding to AT, we
utilized GOLD208 as the GA and assessed the tendency of GlcAp2S and GlcNp2S
monosaccharides to localize to specific sites on AT. The tendencies were quantified using
a grid-based approach as shown in Figure 27. Interestingly, both monosaccharides
displayed statistically significant enrichment (p < 2.2e-16) in the regions that compare
favorably with D (GlcNp2S6S) and E (GlcAp) residues of the heparin pentasaccharide
sequence known to bind AT with high affinity (Figure 26). It may be noted that the D and
E residues have previously been shown as predominantly responsible for affinity with
antithrombin.14 Significant enrichment at these locales suggested excellent probability of
favorable and selective recognition of AT.
To evaluate the predicted interactions more quantitatively, the poses of each
monosaccharide were parsed into two groups using k-means clustering to differentiate
between specifically interacting and randomly interacting poses, as routinely performed
for such studies.209,210 The average pair-wise RMSD for each group was then calculated.
Interestingly, GlcAp2S and GlcNp2S were found to exhibit low RMSDs of 1.2 and 1.0 Å
respectively (Table 9), which suggest a strong possibility of specific interaction with AT
at this locale (Figure 26C and D). It is important to note that we typically use a RMSD
cut-off 2.5 Å to differentiate ‘specific’ from ‘nonspecific’ interactions91,128 and both of
these monosaccharides appear to exhibit a clear preference for HBS of AT.
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Figure 26. Computational studies with the HS2S2S sequence. (A) Almost 50% of naturally
occurring disaccharides possess a higher polar surface area (PSA) than the HS2S2S
disaccharide, but the antithrombin binding heparin pentasaccharide (DEFGH) possesses a
similar PSA. (B) However, DEFGH possesses significantly higher negative charge
density. Thus, HS2S2S is a relatively hydrophobic molecule. Computation predicts specific
interactions formed between antithrombin and HS2S2S monosaccharides (C) GlcAp2S,
corresponding to the D monosaccharide of DEFGH (GlcAp2S6S), and (D) GlcNp2S,
corresponding to E (GlcAp). These interactions were identified using a grid-based
procedure to monitor locales for monosaccharides placed by a genetic algorithm208 used
previously14, 18 to study GAG-protein interactions.
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Figure 27. Grid-based identification of preferred locations for GlcAp2S and GlcNp2S in
genetic algorithm-based docked poses. 2S2S sequences were docked into antithrombin’s
HBS and preferences of the HS2S2S monosaccharides were identified using a grid-based
approach. A high resolution (1Å) grid was placed around the docked hexasaccharide
poses. Any instances of GlcAp2S and GlcNp2S, the center of whose pyranosyl ring was
closest to a grid point, was recorded as being placed at that grid point. The relative
frequency with which a monosaccharide was placed at a grid point – compared to other
grid points – reflects the probability that it will prefer binding there, which was
significantly high (p<2.2e-16).
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Table 9: Data for preferred locations of GlcAp2S and GlcNp2S.
Residue

GlcAp2S

GlcNp2S

% posesa p-value RMSDb % posesa p-value RMSDb

Protein
Antithrombin

16.9%

<2.2e-16

1.2

15.7%

<2.2e-16

1.0

a

: Percent instances (poses) of respective residue at highest density location.
: Average RMSD per pyranosyl ring heavy atom (in Å) within cluster (see Experimental
Section). Smaller values denote highly conserved interactions.
b

4.2.3 Digestive Analysis of HS2S2S using RPIP UPLC-MS
In order to identify the structural composition of the HS2S2S polymer, an enzymatic
digestion

was

followed

using

two

UPLC-MS

methods

to

analyze

heparin

oligosaccharides (Method 1) and disaccharides (Method 2).211-213 After 5 hours of
digestion, no oligosaccharides were observed. However, after 24 hours several
tetrasaccharide peaks were observed (Figure 28A). The mass spectra of these peaks led to
the identification of tetrasaccharides with 2,3 or 4 sulfate groups (T-2S, T-3S and T-4S
respectively) (Figure 28B). At 24 hours some polymeric ions were observed indicating an
incomplete digestion. In comparison, a control batch of unfractionated heparin showed
almost complete digestion within this time (Figure 29). The UV profiles for the sample
demonstrated that the majority sample consisted of tetrasaccharide with 4 sulfate groups
(data not shown). At 48 hours complete digestion to disaccharide level was observed
(Figure 30). The disaccharide analysis (Method 2) identified that the sample of HS2S2S
consisted of mainly disulfated disaccharide with some traces of monosulfated
disaccharides (Figure 30). This was as expected from the observations in method 1.
Furthermore, based on the elution times, the monosulfated disaccharide is possibly
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sulfated at the N-position of the glucosamine similar to heparin disaccharide standard
IVS, while the disulfated disaccharide most likely has a sulfation pattern similar to
heparin disaccharide standard IIIS and is the major peak in the sample.
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Figure 28. Reversed Phase Ion Pairing (RPIP) UPLC-MS total ion chromatogram (TIC)
obtained after 24 hours digestion of HS2S2S using heparanase I, II and III. The
chromatogram shows the presence of tetrasaccharides with 2, 3 and 4 sulfate groups (T2S, T-3S, and T-4S respectively) while also showing undigested polymeric ions. (B) The
mass spectra in positive mode for the different tetrasaccharides showing the loss of ionpairing agent: octylamine (130m/z) while also showing the fragmented core of
tetrasaccharide (m/z = 676).
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Figure 29. Total ion chromatograms using Method 1 of RPIP-UPLC-MS for
unfractionated heparin (UFH) and HS2S2S after 24 hours. While, HS2S2S shows the
presence of polymeric ions, UFH shows almost complete digestion to tetrasaccharide
level. Additionally UFH shows the presence of a tetrasaccharide with 4 sulfate groups
which is absent in HS2S2S.
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Figure 30. Comparison of disaccharide composition of HS2S2S with known heparin
disaccharide standards. The major peak HS2S2S is the disulfated disaccharide which
correlates well with the 2-sulfated and N-sulfated heparin disaccharide standard IIIS.
HS2S2S also shows the presence of a monosulfated disaccharide, which correlates well
with the N-sulfated heparin disaccharide standard IVS.
4.2.4 HS2S2S Potently Interacts with AT
To put the computational prediction of HS2S2S–AT interaction to test, we measured the
affinity of the HS variant for antithrombin. The interaction of HS2S2S with AT was
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followed using intrinsic tryptophan fluorescence following literature reports.156 A
characteristic decrease followed by gradual saturation was observed for fluorescence
emission at 340 nm (λEX = 280 nm) under pH 7.0, I 0.06, 25 ºC conditions, which could
be analyzed using the standard quadratic binding eq 3 to yield an AT binding affinity of
~90 nM (Figure 31, Table 10). In comparison, the affinity of full length unfractionated
heparin (UFH) and homogenous heparin pentasaccharide (H5) for AT under pH 7.4, I
0.15, 25 ºC conditions have been measured to be ~10 and ~50 nM.14,57 This implies that
HS2S2S binds AT with lower affinity than UFH and H5. However, considering the
complete absence of the critical GlcNp2S3S6S residue in HS2S2S (plus the absence of the
adjacent residues that enhance the affinity of H5), the affinity is high. For polymeric
heparin devoid of the GlcNp2S3S6S residue, an antithrombin affinity of 19 mM has been
measured at pH 7.4, I 0.15, 25 ºC, which supports the conclusion that HS2S2S potently
binds AT.
Table 10: Equilibrium dissociation constant (KD) and maximal fluorescence change
(DFMAX) for HS2S2S – coagulation proteins complexes.a
Human Protein

ΔFMAX
(%)

KD
(µM)

Antithrombin

-21±2b

0.09±0.03

Heparin co-factor II

-29±2

2.16±0.27

Thrombin

-37±2

0.49±0.09

Factor Xa

N/Ac

>>100

a

Measured using intrinsic (Trp) or extrinsic (fluoresceinylated protein) fluorescence in 20
mM Sodium phosphate buffer, pH 7.0, containing 25 mM NaCl, 0.1mM EDTA, 0.1%
w/v Peg 8000 at 25 °C. See Experimental Section for additional details. bError represents
±1 S.E. cnot applicable
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Figure 31. Affinity of HS2S2S for antithrombin (A), heparin cofactor II (B), thrombin (C)
and factor Xa (D). Interaction of HS2S2S with the proteins was studied by following the
proportional change in fluorescence (ΔF/F0) as a function of concentration in 20 mM
sodium phosphate buffer, pH 7.0, containing 25 mM NaCl at 25 °C. The saturable
decrease in Trp (for AT, λEX = 280 nm, λEM = 340 nm), TNS (for HCII, λEX = 330 nm,
λEM = 448 nm) or fluorescein (Thr, λEX = 490 nm, λEM = 520 nm) fluorescence was fitted
using quadratic eq 3 (solid line) to derive the maximal fluorescence change (DFMAX) and
equilibrium dissociation constant (KD). Essentially no change in fluorescein fluorescence
was noted for factor Xa (D). See ‘Experimental Section’ for additional details.
4.2.5 HS2S2S Accelerates AT Inhibition of FXa really well
To assess the influence of HS2S2S on the ability of AT to inhibit its two primary enzyme
targets, we studied the kinetics of inhibition of FXa in a discontinuous assay at pH 7.4, I
0.06, 25 ºC, as described earlier. The exponential decrease in residual FXa activity as a
function of time was used to derive the observed pseudo-first order rate constant (kOBS)
(Figure 32). The profile kOBS versus the concentration of HS2S2S–AT complex was found
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to be linear (Figure 32), as expected, which could be fitted by eq 2 to obtain the secondorder rate constant for the uncatalyzed inhibition (kUNCAT) from the intercept and HS2S2S
catalyzed inhibition of FXa from the slope (kHS).
The kUNCAT was found to be 1490 M-1s-1, which is ~1.5-fold lower than that
measured at pH 7.4, I 0.15, 25 ºC57 and in line with the expectations arising from the
reduced activity of the serine proteinase at the lower pH of the experiment. The kHS was
measured to be 323,300 M-1s-1, which translates to an increase of ~217-fold in the rate of
FXa inhibition in the presence of saturating levels of HS2S2S. This is a major acceleration
in the efficacy of AT inhibition of FXa and compares favorably with an acceleration of
~300-fold brought about by H514 or ~600-fold induced by UFH.57 In contrast, full length
heparin devoid of the GlcNp2S3S6S residue accelerates AT inhibition of FXa by only
about 70-fold. This implies that HS2S2S induces AT activation through the conformational
mechanism.
The kinetics of AT inhibition of TH in the presence of HS2S2S was also studied in
a similar manner at pH 7.0, I 0.06, 25 ºC (Figure 32). The kUNCAT and kHS were found to
be 1,060 and 80,600 M-1s-1, respectively, which implies an acceleration of ~76-fold in the
rate of TH inhibition in the presence of saturating levels of HS2S2S. In comparison, UFH
accelerates TH inhibition by AT nearly 1000-fold and absence of GlcNp2S3S6S in the
full-length chain does not introduce any defect in this acceleration.45 H5, on the other
hand, induces only 1.7-fold increase in rate constant.43 These results suggest that HS2S2S
activation of AT for inhibiting TH is not the traditional bridging mechanism, although the
chain length of HS2S2S is similar to that of UFH. This aspect is further discussed below.

97

Residual Factor Xa
Activity (%)

A
100

0 nM

80

10 nM

2.5 nM

25 nM

60
40
20

0
0

4000

Residual Thrombin
Activity (%)

B

12000

16000

(sec)
0 nM

100

5 nM

80

15 nM
50 nM

60
40
20

0
0

4000

Time

C
Residual Thrombin
Activity (%)

8000

Time

8000

12000

(sec)
0 uM

100

0.5 uM

80

1.5 uM

5.0 uM

60
40
20
0

0

8000

Time

D
8.0

16000

24000

(sec)

AT-FXa

kOBS (s-1×103)

AT-Thr
HCII-Thr

6.0
4.0
2.0
0.0
0

10

20

30

40

[HS2S2S - Serpin Complex] (nM)

Figure 32. Kinetics of serpin (AT or HCII) inhibition of coagulation enzymes (TH or
FXa) in the presence of HS2S2S in 20 mM sodium phosphate buffer, pH 7.0, containing 25
mM NaCl at 25 °C. The residual protease activity was measured from the initial rate of
Spectrozyme FXa (A) or Spectrozyme TH (B and C) hydrolysis under pseudo-first-order
conditions as a function of time in the presence of different concentrations of HS2S2S and
fixed concentrations of AT (A) and HCII (B and C). The profile of the observed pseudofirst order rate constant of inhibition (kOBS) at each HS2S2S concentration was analyzed
using linear eq 4 to calculate the uncatalyzed (kUNCAT) and catalyzed (kHS) rate constant of
inhibition from the intercept and slope of the fitted lines (solid lines). See ‘Experimental
Section’ for additional details.
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4.2.6 Specificity of HS2S2S Interaction with Coagulation Proteins
To assess whether HS2S2S targets proteins related and relevant to the AT system, we
studied its interaction with HCII, TH and FXa using spectrofluorometry at pH 7.0, I 0.06,
25 ºC. Unfortunately, the change in intrinsic tryptophan fluorescence could not be used
for these three proteins because of a small signal. Hence, extrinsic fluorophores were
utilized including TNS for HCII and fluorescein for TH and dansyl for FXa, which have
been utilized earlier.155,205 A saturable decrease in extrinsic fluorescence was found for
HCII and TH suggesting that HS2S2S binds with an affinity of 2.2 and 0.5 µM,
respectively (Figure 31, Table 10). In contrast, essentially no change in fluorescence was
observed for HS2S2S–FXa system suggesting minimal interaction (>>100 mM). The
results suggest that HS2S2S binds to both HCII as well as TH with fairly high affinity,
although it prefers AT by at least 5.5-fold. The dermatan sulfate–HCII and UFH–TH
systems have been reasonably well studied and display affinities in the range of 0.5–50
µM at pH 7.4.155 Likewise, the affinity of a high affinity dermatan sulfate hexasaccharide
for HCII has been reported to be 20 µM.92 Thus, although a direct comparison of the
affinities is not possible because of differences in conditions, HS2S2S binds to HCII and
TH with affinities either comparable to or better than other GAGs.
4.2.7 HS2S2S accelerates HCII inhibition of TH
To assess whether the dual interaction of HS2S2S is an aid or barrier to HCII inhibition of
TH, we studied the kinetics of inhibition (Figure 32). The second-order rate constant of
HCII inhibition of TH was measured in a manner similar to that for AT through
discontinuous measurement of pseudo-first order rate constants at varying HS2S2S
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concentrations. HCII inhibition of TH was also accelerated ~38-fold by HS2S2S (Table
11). In comparison, full-length heparin and dermatan sulfate are known to accelerate this
reaction greater than 2000-fold predominantly through a conformational change
mechanism.155 The literature reports that HCII–UFH system is a non-specific system,155
which implies that even if HS2S2S was binding to HCII in a non-specifically manner, an
activation significantly higher than 38-fold should have been observed. This implies that
most probably favorable binding to TH in addition to HCII is most probably limiting full
activation potential of HS2S2S.
Table 11: Acceleration in serpin inhibition of coagulation enzymes brought about by
HS2S2S.a
Serpin – Enzyme
kUNCAT
kHS
Accelerationb
System
(M-1s-1)
(M-1s-1)
AT – FXa

1490±200c

323,300±7,560

217±34

AT – Thr

1060±100

80,600±8,200

76±15

HCII – Thr

1090±100

36,800±1,320

34±4

a

Measured using discontinuous enzyme inhibition assay in 20 mM Sodium phosphate
buffer, pH 7.0, containing 25 mM NaCl, 0.1mM EDTA, 0.1% w/v Peg 8000 at 25 °C.
See ‘Experimental Section’ for additional details. bRefers to the ratio of catalyzed and
uncatalyzed rate constants. cError represents ±1 S.E.
4.2.8 HS2S2S Directly Inhibits TH, but not FXa
To assess whether HS2S2S directly inhibits target proteases, TH and FXa, we measured
their residual activity in the presence of HS2S2S using chromogenic substrate hydrolysis
assay, as described earlier.207 Interestingly, TH activity decreased as a function of HS2S2S
concentration, which could be fitted using the logistic dose-response eq 3 to obtain an
IC50 of 4.3±0.3 µM (Figure 33) and an efficacy of 40±1.3 %. In contrast, FXa activity
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remained214,215 essentially unaffected even at 100 µM HS2S2S. 47, 48 Although a number of
studies report GAG binding to thrombin,134,216 this is the first demonstration of direct TH
inhibition. We have previously reported a group of polymeric sulfated GAG mimetics as
potent direct inhibitors of TH (and also of FXa). These sulfated GAG mimetics were
significantly more hydrophobic than GAGs and were found to bind to exosite II of
thrombin and induce allosteric inhibition. In a similar manner, we hypothesize that
HS2S2S also exhibits allosteric inhibition of thrombin. This implies that HS2S2S is able to
exploit a major difference in heparin-binding sites of two highly similar serine proteases.
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Figure 33. Studies on direct inhibition of thrombin (") and factor Xa (#) by HS2S2S.
Protease inhibition was measured spectrophotometrically through chromogenic substrate
hydrolysis assay in 20 mM sodium phosphate, pH 7.0, containing 25 mM NaCl at 25 °C.
Solid lines represent sigmoidal fits to the data using eq 3 to obtain IC50, YM and Y0. See
‘See experimental Section’ for additional details.
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4.3 Discussion
4.3.1 Rare Saccharide Sequences as a means to Identify Novel Interactions
The strategy of utilizing rare saccharide sequence have been fruitful in the identification
of novel interactions and can serve as an efficient tool. Numerous reported examples
showcase the importance of other rare sequence like the 3-O sulfate glucosamine residue
among similar examples. The 2-O sulfate glucuronic acid we studied is another such rare
sequence and is interesting from the chemical biology perspective especially in
unearthing novel interaction with known coagulation systems.
4.3.2 Differential Affinity and Specificity of HS2S2S allows Probing of Coagulation
Cascade Pathways
The accelerated inhibition of thrombin by antithrombin occurs mainly by a bridging
mechanism, where the main driving force is co-localization of antithrombin and thrombin
on the surface of heparin, which requires high-affinity, high-specificity antithrombinheparin and low-affinity, low-specificity thrombin-heparin interactions.43 Discovery of
the HS2S2S polymer is a unique event because it possesses high affinity (≤ 500 nM) for
both, antithrombin and thrombin. This enables us to deduce the effects of high affinity on
coagulation pathways. As observed, HS2S2S accelerates inhibition of thrombin by
antithrombin only by 76-fold (Table 11), compared to ~2,400-fold, as observed
previously.43 On the other hand, HS2S2S accelerates inhibition of FXa by antithrombin
217-fold, which is similar to previous observations.46,217 The reason for this reduced
thrombin-inhibition compared to unchanged FXa-inhibition by antithrombin lies in the
mechanism of action exerted by the participating GAG. Antithrombin-mediated FXa
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inhibition is mainly due to conformational change induced by heparin, which is clearly
also exerted by HS2S2S, and is perhaps caused by specific electrostatic interactions.
However,

previous

studies

for

the

antithrombin-heparin-thrombin

interaction

comprehends a ~1.7-fold conformational and ~2400-fold bridging mechanism attributed
to the acceleration.43 The antithrombin-HS2S2S-thrombin system possibly maintains the
conformational aspect however, due to the increased affinity towards TH, loses the
bridging mechanism and accounting for the vast loss of acceleration.
The HCII-heparin-thrombin system shows a ~2400-fold activation of the serpin
with ~7-fold attributed to bridging and ~2400-fold attributed towards conformational
activation. The low 34-fold acceleration seen in the presence of the HS2S2S polymer thus
indicates a lower specificity of interaction incapable of replicating a similar level of
conformational activation as heparin. However, a miniscule level of activation is
observed, serving as a proof of the concept that affinity need not necessarily translate into
high specificity.
4.3.3 Direct Inhibition of Heparin is a Previously Unknown Effect
Thrombin-heparin interactions have been widely reported to be non-specific. Heparin is
known to bind to the exosite II of thrombin, but does not produce any direct inhibition of
thrombin. Thus, the direct inhibition of thrombin observed here is a novel effect. The
mode of action here perhaps cannot be described by the model employed here to assess
specificity of interactions between thrombin and HS2S2S because heparin is not known to
manifest a similar inhibition by binding at this site. This also lays stress on the study of
rare disaccharides in glycobiology.
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4.3.4 Computational Studies can Predict Protein-GAG Specificity and Affinity
Our work provides a good platform to showcase the utilization of computational tools in
understanding complex systems and designing agents by a systematic approach to allow
for more predictable outcomes. Heparin and heparan sulfate are notoriously
heterogeneous systems with a variety of saccharide compilations and sulfation patterns
making it a difficult system to work with in an experimental setting. Utilizing the
computational resources at our disposal we have attempted to decipher specific nonnatural monosaccharides/disaccharides present in the abundant H/HS library. The in vitro
results thus obtained were expected, based on our design strategy. Thus, this serves as
platform to further utilize computational design strategies to provide prediction in the
outcomes when dealing with such complex mixtures.
4.4 Experimental Section
4.4.1 Computational Methods
Preparation of a Library of HS Hexasaccharides for Computational Studies
Ten HS disaccharide sequences containing GlcAp2S or GlcNp were constructed using
SybylX v. 2.0. The sequences incorporated all the known natural variations at the 2-, 3and 6-positions of the two residues. These disaccharides were then used to construct a
combinatorial library in which oligomerization at the C-4 and C-1 positions was
performed by deletion of appropriate atom(s) and addition of a desired disaccharide
sequence. The operations were repeated in an automated manner to produce a library of
9918

hexasaccharide

sequences
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containing

at

least

one

!4)GlcAp2Sβ(1!4)GlcNp2S(1! or !4)GlcNp2Sα(1!4)GlcAp2S(1! disaccharide
sequence.
Docking of HS2S2S-containing Hexasaccharide Library onto AT
The AT structure used in these studies was 1TB6134 and was prepared using Sybyl’s
“prepare protein” option. Hydrogens were added and minimized using the Tripos force
field and Gasteiger-Hückel charges. The library of 9918 HS2S2S sequences was docked
into the heparin-binding site of AT using GOLD,208 which uses a genetic algorithm to
place ligands into the binding site. Each hexasaccharide sequence was docked using 100
GA runs, each consisting of 100,000 iterations. A 16 Å docking radius around the NZ
atom of Lys125 was used, which is approximately in the center of the heparin-binding
site of AT. The inter-glycosidic linkages of the hexasaccharides were maintained rigid at
the average phi and psi values derived from the literature.18 The GA runs were allowed to
terminate early if the top three solutions had an RMSD of 2.5 Å or lower, of which the
two best poses were stored and analyzed at the end of the docking experiment. GoldScore
was used to assess the fitness of the docked poses.
Grid-based Screening of Protein-monosaccharide Interactions
The overall scheme describing assessment of specific and high-affinity proteinmonosaccharide interactions is described in Figure 27. In-house python scripts that
incorporated the Openeye OEChem toolkit218 were used to investigate the residence
tendencies of monosaccharides on protein HBSs. A grid was generated around the
docked 2S2S-containing hexasaccharides to analyze preferences in location of
monosaccharides. A density map was obtained by counting the number of times a
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monosaccharide resided closest to a grid point. Statistical significance of monosaccharide
enrichment at its highest-density location compared to other locations on the grid was
analyzed using a proportionality test in the R statistical programming environment.
Clustering and Statistical Evaluation
A k-means clustering algorithm for comparison of molecular positions was generated inhouse using the Openeye OEChem toolkit.218 The algorithm was specifically asked to
search for 2 clusters amongst a group of monosaccharide positions, maximizing the
distance between the cluster centers. This enabled identification of the “tightest” cluster,
i.e. showing least deviation in atomic positions of the pyranose ring, as measured by the
RMSD metric. All statistical analysis was conducted using the R statistical
environment.304
4.4.2 Proteins and Chemicals
Human plasma AT, HCII, thrombin (TH), fluorescein tagged TH (FFPRCK-TH) and
fluorescein tagged human FXa (FXa-DEGR) were purchased from Haematologic
Technologies (Essex Junction, VT) and used as such. The proteins were stored in 20 mM
sodium phosphate buffer, pH 7.0, containing 25 mM NaCl, 0.1 mM EDTA and 0.1%
(w/v) PEG8000 at -80 °C. Spectrozyme FXa and thrombin were obtained from American
Diagnostics (Greenwich, CT). TNS ((2-(p-toluidino)naphthalene-6-sulfonic acid) was
purchased from Sigma Aldrich (Milwaukee, WI). Anhydrous CH3CN and, NH4OAc,
acetic acid were purchased from Fisher scientific (Pittsburgh, PA) and used as such.
Tributylamine (TrBA), octylamine (OTA) were purchased from Acros organics (New
Jersey, NY). All these reagents were of a high purity LC/MS grade quality. Heparin
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standards

(1,1,1,3,3,3-Hexafluoro-2-propanol)

were

obtained

from

Galen

labs

(Middletown, CT) whereas, the unfractionated heparin was purchased from Sigma
Aldrich (Milwaukee, WI).
4.4.3 Mass Spectrometry Studies
Enzymatic Digestion
An enzymatic digestion on 320 µg of HS2S2S or porcine unfractionated heparin (UFH)
was performed in 40 µL volume. The sample was treated with heparinase I, II and III (5
mIU each/ 1mg substrate). The mixture was incubated in the Acquity H-Class UPLC
sample’s manager (Waters) for 75 h at 37 °C. Direct sampling of 5µL from the reaction
mixture was performed and injected into the UPLC-MS after 5, 26, 48 and 75 h using the
following technique of reversed-phase ion-pairing (RPIP).
RPIP UPLC-MS
All analyses were carried out with Waters Acquity H-Class UPLC system coupled to
Waters Acquity TQD detector (Milford, MA). There are several UPLC-MS techniques in
the literature for analysis of GAGs oligosaccharides and disaccharides.43-45 We performed
a time-based digestion of HS2S2S and unfractionated heparin (as control) using
heparinases I, II, and III. The initial formation of oligosaccharides was monitored using
Method 1, while the disaccharide composition upon complete digestion was examined
using Method 2.
Method 1
For analysis of oligosaccharides during the initial stages of digestion (5 and 26h), we
adopted the UPLC separation method and MS parameters described by Robert J. Linhardt
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et al. and Cynthia K. Larive et al. with some modifications.213 The reversed phase
separation was performed by injecting 5µL of the digestion mixture onto an Acquity
UPLC BEH C18 1.7 µm (2.1 x 150 mm) column with a guard column. The temperature
of the column was maintained at 40 °C. A gradient of 100% solvent A was maintained at
a flow rate 0.1ml/min for 2 min and raised to 100% of solvent B over 45 min. Solvent A
consisted of Water:ACN (95:5, v/v), and solvent B was (15:85, v/v). Both solvents A and
B contained 15 mM octylamine (OTA) as an ion-pairing reagent and 100 mM HFIP as
organic modifier. The outlet from the column was passed through an Acquity PDA
detector and directly infused into the mass spectrometer. The ESI-MS was performed in
positive ionization mode with a capillary voltage of 3.20 KV, extractor voltage of 1V,
radio frequency of 0.1V, source temperature of 150 °C, and desolvation temperature of
350 °C. MS scans between 500-2000 m/z were obtained at different cone voltages
ranging from 20V-100V in 20V increments so as to monitor in source fragmentation.
Method 2
For disaccharide analysis after complete digestion (>48hrs), we performed a method
previously demonstrated for heparin disaccharide analysis.213 Briefly, the binary solvent
system contained the same concentrations of ion pairing agent tributylamine (TrBA) 20
mM, ammonium acetate 2.5 mM and acetic acid 22.2 mM. Solvent A and B consists of
Water:ACN (95:5, v/v) and (20:80, v/v), respectively. The pH of the mobile phase was
carefully adjusted at 7. An injection of 5µL of the digestion sample or heparin
disaccharide standard mixture containing 50µg/ml of each standard was made onto the
Acquity UPLC BEH C18 1.7 µm (2.1 x 100 mm) column with a guard column. The
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temperature of the column was maintained at 40°C, while the flow rate was maintained at
0.5ml/min. The ESI-MS was set to negative ionization mode using a capillary voltage of
3.0 KV, extractor voltage of 1V, radio frequency of 0.5V, source temperature of 150 °C,
desolvation temperature of 350 °C. The cone gas flow of 20L/h worked best on our
instrument so as to prevent source contamination. The MS scans were obtained from 2501000 m/z with 20V, 30V and 40V cone voltage settings. An SIR for the various
disaccharides standards was also set up to allow better comparison with quicker scan
times.
4.4.4 Equilibrium Binding Studies using Fluorescence Spectroscopy
The dissociation constant of HS2S2S–protein complexes were measured using change in
fluorescence emission as a function of the concentration of the GAG in 20 mM sodium
phosphate buffer, pH 7.0, containing 25 mM NaCl, 0.1 mM EDTA and 0.1% PEG8000 at
25 °C, as described earlier.176 The experiments were performed using a QM4 fluorometer
(Photon Technology International, Birmingham, NJ) in a quartz microcuvette by titrating
it into a 200 µL solution of the protein (100–250 nM) and monitoring the change in the
fluorescence at either 340 nm (for AT, λEX = 280 nm), 520 nm (for TH, λEX = 490 nm),
448 nm (for HCII, λEX = 330 nm), or 547 nm (for FXa, λEX = 345 nm). The concentration
of TNS used for measuring affinity of HS2S2S for HCII was 10 mM. Excitation and
emission slit width were set to 1.0 mm. The saturable change in fluorescence signal was
fitted using the quadratic equilibrium binding eq 3 to obtain the KD of interaction. In this
equation, ΔF represents the change in fluorescence at a fixed concentration of HS2S2S
from the initial fluorescence F0 and ΔFMAX represents the maximal change in
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fluorescence following saturation of the protein. [P]0 represents the concentration of
either AT, HCII, TH or FXa.
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4.4.5 Kinetics of Protease Inhibition in the Presence of HS2S2S
The kinetics of inhibition of coagulation proteases, TH or FXa, by AT or HCII in the
presence of HS2S2S was measured spectrophotometrically using a microplate reader
(FlexStation III, Molecular Devices) under pseudo-first-order conditions, as described
earlier.82 Briefly, a fixed concentration of TH or FXa (5 nM) was incubated with fixed
concentrations of plasma AT (100 nM) or HCII (50 nM) and HS2S2S (0 – 5000 nM) in 20
mM sodium phosphate buffer, pH 7.0, containing 25 mM NaCl, 0.1 mM EDTA and 0.1%
(w/v) PEG8000 at 25 °C. At regular time intervals, an aliquot of the inhibition reaction
was quenched with 100 µL of 125 – 200 µM chromogenic substrate (Spectrozyme TH or
Spectrozyme FXa) in 20 mM sodium phosphate buffer, pH 7.0, containing 25 mM NaCl
at 25 °C. To determine the residual protease activity, the initial rate of substrate
hydrolysis was measured from the increase in absorbance at 405 nm. The exponential
decrease in the initial rate of substrate hydrolysis as a function of time was used to
determine the observed pseudo-first-order rate constant of protease inhibition (kOBS). A
plot of kOBS at different concentrations of HS2S2S–serpin complex could be described by
eq 4, in which kUNCAT is the second-order rate constant of protease inhibition by serpin
alone and kHS is the second-order rate constant of protein inhibition by serpin-HS2S2S
complex (HS2S2S:P).
!!"# = ! !!"#$% [!]! + ! !!" ![!"!!!! : !]

110

(4)

4.4.6. Direct Protease Inhibition in the Presence of HS2S2S
Direct inhibition of TH or FXa was measured through a chromogenic substrate hydrolysis
assay using a microplate reader (FlexStation III, Molecular Devices), as described
earlier.177 Briefly, each well of the 96-well microplate contained 190–X µL of pH 7.0
buffer to which X µL of HS2S2S (to give 0 – 25 µM final concentration), or reference, was
added followed by 5 µL of protease (to give 5 nM final concentration). After 10 min
incubation at 25 °C, 5 µL of appropriate chromogenic substrate (to give 125 mM
(Spectrozyme FXa) or 200 mM Spectrozyme TH) was rapidly added and the residual
protease activity was measured from the initial rate of increase in A405. Relative residual
protease activity at each concentration of HS2S2S was calculated from the ratio of the
activity in the presence and absence of the inhibitor. The dose – response profile was
fitted by eq 5 to calculate the potency (IC50) and efficacy (ΔY = YM – Y0) of inhibition.
In this equation, Y is the relative residual protease activity, YM and Y0 are the maximum
and minimum values of the relative residual protease activity, IC50 is the concentration of
HS2S2S that results in 50% inhibition of protease activity and HC is the Hill slope.
! = ! !! + !
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CHAPTER 5: SULFATED QUINAZOLIN-4(3H)-ONES AS ALLOSTERIC
MODULATORS TARGETING FXIa.
5.1 Introduction
Advances in the field of anticoagulants have been abundant and continuous over recent
years Yet, thromboembolism continues to be a major concern in the clinical set up.10 The
direct inhibitors of FXa and thrombin have progressed considerably with newer drugs
being added to this class of inhibitors.219 Nonetheless, the bleeding risks associated with
the older agents have been persistently seen at an alarming rate within the newer
generation of anticoagulants as well, making it vital to develop newer strategies to
develop safer agents.220,221 Generally, FXa and thrombin which, belong to the common
pathway of the cascade, are known to be essential from the initiation and propagation
perspectives. However, proteases belonging to the intrinsic pathway are primarily
involved in the amplification of the coagulation signal.9,11 A hypothesis that is gradually
gathering pace involves engaging proteases in the intrinsic pathway.221 Proteases such as
FXIa can be targeted to develop safer antithrombotics compared to FXa and thrombin.
Current studies have indicated that depleting FXIa levels reduces thrombotic
complications whilst leaving the hemostatic system intact.9,11,105 Similarly, absence of
FXI was found to cause mild bleeding disorders whereas; the occurrence of ischemic
stroke was evidently reduced in such patients.108 Elevated FXI levels were found to
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enhance risk of venous thrombosis and cardiovascular diseases in women.105-107
Consequently, FXIa could serve as a more efficient and safer target.
GAGs including heparin are known to interact with a number of enzymes in the
coagulation cascade.222 A major problem in discovering GAG-based molecules, however,
is the rather poor specificity of interaction of these with proteins.129,222,223 This is
generally due to the nature of the forces that are responsible for interactions that are
electrostatic in nature and predominantly nondirectional and operational over long
distances.222 This implies that these could, therefore, non-selectively recognize any
positively charged domain of a protein severely limiting its selectivity profile. Strategies
designed to overcome these problems range from the application of small saccharide
units with limited anionic groups (sulfates, phosphates, carboxylates) like the
oligosaccharides containing sulfate and phosphate apatamers, sulfated-linked cyclitols,
and dendritic polyglycerol sulfates.133,224-226 Another concept utilizes sulfate decorated
small

molecules

like

sulfated

flavones,

sulfated

xanthones

and

sulfated

tetrahydroisoquinolines.82,176
5.1.1. Hypothesis
The field suffers from the lack of a generalizable strategy for the rational design of
modulator of GAG-protein interactions. Consequently a rational strategy was devised in
the Desai laboratory, which involves the utilization of the hydrophobic (hP) domain near
the heparin binding sites (HBS) of proteins.206 This domain has been observed to be
different in various proteins and thus we hypothesized that it should be possible to
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discover molecules, herein called as sulfated allosteric modulators (SAMs), by exploiting
differential recognition of hP patches around the HBS. This strategy is postulated to
recognize the binding site in two steps which involves (1) initial attraction of an anionic
sulfate group present on a SAM to the one or more electropositive lysine/arginine
residues located in the heparin-binding protein (HBP) followed by (2) recognition of an
adjacent hP patch on the HBP to form a complex (Figure 34). Thus, if this strategy is
valid, enzymes devoid of either the electropositive HBS or the hP domain would not
favorably interact with the SAM and thereby lack inhibition. Enzymes possessing both
the electropositive HBS and the hP will be targeted by SAM. However, the potency of
inhibition is dependent on the complementarity of the SAMs hydrophobic scaffold with
the hP domain on the enzyme. Briefly, this strategy revolves around the electronic
steering of the small molecule to the HBS of the protein due to nondirectional initial,
weak ionic bond followed by filtering and tight locking of an optimal hydrophobic SAM
scaffold.206
5.1.2. Studies on first generation of quinazolin4-(3H)ones (QAOs) as allosteric
inhibitors of FXIa
The dual element hypothesis (Figure 34) was examined by a library of 26 QAOs
including 7 monomers and 19 dimers containing 1-4 sulfate groups. This scaffold is a
well-known hP scaffold with three-dimensional similarity to flavonoid scaffold studied
earlier as heparin binding site (HBS) ligand.176,227,228 The monomers were synthesized
using simple condensation techniques (see experimental section) and then sulfated.229
Inhibition data however, revealed lack of any activity against fXIa. To further diversify, a
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library of 19 dimers was synthesized; each designed to probe specific features of the
fXIa-binding site. In general, these could be classified on the basis of the feature probed,

Figure 34. Strategy for the design of a SAM of a GBP exploiting the difference in
hydrophobicity (hP, shown as light colored patch) on the periphery of a HBS (shown as
blue ellipse with positive charges). A SAM binds an enzyme (shown by red dashed line),
e.g., E1, only if it contains both hP and HBS. E2 and E3 do not recognize the SAM
because of an absence of either hP or HBS. This generates selectivity of recognition.206
(Adapted from reference 206).
1) Number of sulfate groups- In general, monomers containing a single sulfate group
were found to be inactive. Similarly, dimers containing a single sulfate group were
not potent either. Only dimers containing two sulfate groups, one sulfate group on
each dimer were deemed active (Figure 35A). However, dimers possessing 3 or 4
sulfates displayed a reduced potency towards fXIa.206
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2) The core quinazolinone scaffold- Around 14 compound possessed the
quinazolinone scaffold to form the dimer. (Figure 35A), which though not symmetric
in the technical terms, were referred to as the homo-dimers due to the incorporation
of a quinazolinone scaffold on both the monomers. The activity for such compounds
ranged from (50-320 µM). To test the structural dependence of the hP domain,
flavonoid-containing dimers were synthesized. These involved the incorporation of a
flavonoid scaffold additionally; these were decorated with 4 sulfates and hence the
term hetero-dimers (Figure 35C). However, these lacked any activity against fXIa
thereby indicating the importance of the quinazolinone scaffold.
3) The linker length and geometry- The linker length and geometry were examined
through the synthesis of compounds containing varying length (8-11) of intervening
atoms. Similarly, the geometric constraints were varied through the use of 1,4(Figure 35A) or 1,5-triazole (Figure 35D) and the two-triazole linker analogs (Figure
35B). IC50 studies with this set indicated increasing potency with increasing linker
length; similarly, the 1,4- triazole geometry was found to be more suitable to maintain
potency.

However, the need to introduce a more extensive search to further

understand this domain was deemed to be essential to enhance potency and improve
selectivity.
4) The position of the sulfate groups- For active dimers decorated with two sulfate
groups, the presence of a sulfate group at the para-para position was more favorable
as compared to its positioning at the meta-para position and the meta-meta positions.
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Figure 35: The library of first generation QAO dimers. A. Quinazolinone dimer with a
1,4-triazole linker B. Quinazolinone dimer with a two triazole rings in the linker C.
Mixed dimer containing a flavonoid scaffold D. Quinazolinone dimer with a 1,5-triazole
linker.
5.1.3. Mechanism of Inhibition of First Generation Sulfated Quinazolinones
Mechanistic studies provided insights into the functioning of these molecules, primarily
indicating key features
1. All these molecules indicated a lack of potency against other serine proteases in the
coagulation and the digestive system (FXa, thrombin, trypsin and chymotrypsin)
indicating the success of the dual element strategy.
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2. Michaelis-Menten studies indicated these to be functioning through a noncompetitive mechanism, which was a major design goal of the dual element strategy.
3. Mutagenesis studies indicated the location of binding to be around the heparinbinding site within the catalytic domain. Similarly, studies involving neutralization of
the charge interaction through the use of an electropositive polymer confirmed the
functioning through the hP domain.
4. Fluorescence-based affinity studies shows a sigmoidal profile suggestive of a
cooperative binding process, further confirmed by the high Hill coefficient (6.4-9.0).
These extensive studies therefore, laid the foundations for confirming the functioning of
the dual element strategy as well as providing insights into the mechanism of action of
these agents.
5.1.4. Updated Hypothesis: Second Generation of FXIa Inhibitors
The first generation of allosteric SAMs were beneficial in providing a basic
understanding of the dual element strategy and the functioning of this system. Utilizing
the important inferences obtained through these studies, we have tried to improve on the
general features like the potency and understanding the of the mechanism understanding
of this class of molecules. A major domain that we postulated to have large effects on the
potency of these molecules was the linker domain. We therefore fragmented the core
structure of the first generation library and split it into 3 major domains: 1. The
hydrophobic domain 2. The linker domain 3. The charged group-containing
domain. (Figure 36)
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Figure 36. Strategy for the design of more potent and selective set of molecules, by
splitting the scaffold into the hydrophobic domain (green), the linker region (red) and the
charged group containing domain (blue)
Previous studies had already established the importance of the quinazolinone based
hydrophobic domain, with the replacement of a flavonoid conferring a decrease in
potency. Similarly, the presence of two sulfates, one on each monomer, is essential to
maintain activity. Modifications in the linker domain indicated the most promise for
developing newer more potent and selective agents. The linker length and geometry was
therefore targeted through a library of molecules with major modifications aimed at this
domain. This work describes the utilization of dual element strategy with further
modifications in the linker domain and the mechanistic outcomes of these
modifications.206
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Figure 37. The structure of 16S, IC50 = 52 µM.

119

N

5.2. Results and Discussions
5.2.1. Synthesis of the Library of QAOs.
In continuation with our initially reported dual element strategy, we synthesized a total of
18 sulfated dimers. These were synthesized with modifications to our reported lead 16S
(Figure 37).206 We employed a new approach to synthesize a library of fairly diverse
compounds with major modifications targeting the linker domain (Figure 36). The
original approach utilized copper-catalyzed azide-alkyne cycloaddition (CuAAC)
reaction, which was used to dimerize the quinazolinone dimers incorporating a triazole
ring in the linker during the process. The new strategy incorporates a simple aromatic or
aliphatic linker by utilizing a simple nucleophilic substitution reaction. Thus, affording a
library of 18 diverse compounds 7S-24S, which could be used to further probe the
heparin-binding site in FXIa and obtain a more detailed understanding of the binding site
of these QAOs.
The QAO core scaffold was synthesized using a condensation reaction between
anthranilamide and suitably substituted benzaldehyde to obtain QAO monomers 2a-2b
containing one phenolic group (Scheme 1). This was followed by protection of the
phenolic group through acetylation in the presence of acetic anhydride and DIPEA,
thereby preparing it for dimerization using a substitution reaction in the presence of
potassium carbonate and the required aryl/alkyl dibromo linker affording a suitable
dimer. These dimers were then deprotected and the resulting intermediates were
subjected to microwave-assisted sulfation to obtain sulfated QAOs 7S-24S (Scheme 2).
All these compounds contain similar monomer units separated by linkers of varying
lengths and could therefore be classified as homodimers. The compounds synthesized
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could be broadly classified on the basis of the linker incorporated into the dimers.
Compounds 7S-11S contain an aromatic linker, which could either be o, m or p-xylene
based. Each of these orients the quinazolinone rings in a distinct geometry and thereby,
could be used to obtain important information on the geometry preferred by the HBS in
FXIa. Compounds 12S-24S incorporate an aliphatic chain that varies in length (4-12) of
carbon atoms. Similarly, two compounds which contains a trans but-2-ene linker (12S)
imparting rigidity and the 1-propoxypropane containing linker (15S) were also
synthesized to assess geometry and hydrogen bonding capability of linker, respectively.
Scheme 1. Synthesis of QAOsa
O

O
NH2
NH2
1

H

O
a) then b)

+

NH
N

R'
2a: R = 3-OH
2b: R = 4-OH

R'

3a: R = 3-OAc
3b: R = 4-OAc

a

Conditions: (a) NaHSO3, p-toluene sulfonic acid, DMAD, reflux/overnight, 85-90%; (b)
Acetic anhydride, DCM, DIPEA, 4-6 h, 85-90%.

121

Scheme 2. Synthesis of Sulfated QAOs 19S-36Sa
R
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4: R= H; R'=3-OAc
5: R=H, R'=4-OAc
6: R=CH3;R' = 4-OAc

O

Aliphatic linkers
Aromatic linkers
Aromatic linkers
7:R=H; R'=3-OH; X= -p-xylene 12:R=H; R'=3-OH -; X= trans-1,4-but-2-ene 7S:R=H; R'=3-OSO 3-; X= -p-xylene
8:R=H; R'=3-OH; X= -m-xylene 13:R=H; R'=3-OH; X= 1,5-pentane
8S:R=H; R'=3-OSO 3-; X= -m-xylene
9:R=H; R'=4-OH; X= -m-xylene 14:R=H; R'=4-OH; X= 1,5-pentane
9S:R=H; R'=4-OSO 3-; X= -m-xylene
10:R=H; R'=3-OH; X= -o-xylene
11:R=H; R'=4-OH; X= -o-xylene15:R=H; R'=3-OH; X= 1-propoxypropane 10S:R=H; R'=3-OSO 3 ; X= -o-xylene
16:R=H; R'=4-OH; X= 1,6-hexane
11S:R=H; R'=4-OSO 3-; X= -o-xylene
17:R=H; R'=4-OH; X= 1,6-hexane
18:R=CH3; R'=4-OH; X= 1,6-hexane
19:R=H; R'=4-OH; X= 1,7-heptane
20:R=H; R'=4-OH; X= 1,8-octane
21:R=H; R'=4-OH; X= 1,9-nonane
22:R=H; R'=4-OH; X= 1,10-decane
23:R=H; R'=4-OH; X= 1,11-undecane
24:R=H; R'=4-OH; X= 1,12-dodecane

a

Aliphatic linkers
12S:R=H; R'=3-OSO 3-; X= trans-1,4-but-2-ene
13S:R=H; R'=3-OSO 3-; X= 1,5-pentane
14S:R=H; R'=4-OSO 3-; X= 1,5-pentane
15S:R=H; R'=3-OSO 3-; X= 1-propoxypropane
16S:R=H; R'=4-OSO 3-; X= 1,6-hexane
17S:R=H; R'=4-OSO 3-; X= 1,6-hexane
18S:R=CH3; R'=4-OSO 3-; X= 1,6-hexane
19S:R=H; R'=4-OSO 3-; X= 1,7-heptane
20S:R=H; R'=4-OSO 3-; X= 1,8-octane
21S:R=H; R'=4-OSO 3-; X= 1,9-nonane
22S:R=H; R'=4-OSO 3-; X= 1,10-decane
23S:R=H; R'=4-OSO 3-; X= 1,11-undecane
24S:R=H; R'=4-OSO 3-; X= 1,12-dodecane

Conditions: (a) K2CO3, aryl/alkyl dibromide, DMF, rt/overnight, 70–80%; (b) LiOH.H2O, THF, rt/4-6 h, 85–90%; (c)
SO3/Me3N, TEA, CH3CN, microwave/30 min, 85−90%.
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5.2.2. Inhibition Profile of Sulfated QAOs against Human Factor XIa and Other
Similar Proteases in the Coagulation and Digestive System
The library of sulfated QAOs was screened for inhibition of human FXIa and other
coagulation enzymes using a chromogenic substrate hydrolysis assay (see Experimental
Section). The sigmoidal decrease in the initial rate of protease activity (on a semilog plot)
as a function of ligand concentration was fitted using the logistic dose-response equation
to calculate the IC50 (Table 12). Each of the 18 molecules displayed some activity against
FXIa (~6.0–415µM). The library of dimers was built using a simple nucleophilic
substitution reaction that provided high yields of the desired compounds. The general
theme of the library design revolved around targeting modifications in the linker domain
(Figure 35). The first generation incorporated of a triazole-based linker; further studies
had highlighted the importance of the linker geometry and length, and these were the two
features we decided to target and further probe to obtain more potent inhibitors, while
maintaining the selectivity. The library can be thought off in two sets: 1) the aromatic
linkers and 2) the aliphatic linkers-containing set.
Aromatic linkers
A set of five dimers were synthesized composed of the xylene-based linkers. Each of
these was synthesized to probe into the geometric element of the linkers. In general, the
ortho, meta and para -xylene linkers were used, each possessing 4, 5 and 6 intervening
atoms, respectively (Table 12). These molecules, however, displayed a progressively
lower potency ranging from 57 to 248 µM. Surprisingly, the shorter ortho (n =4), where
‘n’ is the number of intervening atoms in the linker, and meta (n = 5) linker containing
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dimers displayed a better potency compared to the para (n = 6) xylene linkers. The
positioning of the sulfate group indicating maximal potency was not consistent, with
either the 3-OSO3- or the 4-OSO3- variably preferred. We attribute this to the variable
geometry in each of these molecules. However, these did help us play down the
importance of the triazole ring, which was evidently not required considering the same
level of potency displayed by 11S (Table12).
Aliphatic Linkers
On the basis of our initial study with aromatic linkers we synthesized dimers containing
the 4-6 intervening atoms. To continue with the placement of a rigid structure, 12S (IC50
= 415 µM) was synthesized consisting of an unsaturated trans-but-2-ene linker, however
this was found to lack potency. Our subsequent approach was to use a saturated aliphatic
linker containing 5 carbons. Both the 3-OSO3- (13S) (IC50 = 88.5 µM) and the 4-OSO3(14S) derivatives were synthesized. This approach produced drastic improvement in
potency (Table 12) with (14S) (IC50 = 49.3 µM), the 4-OSO3- derivative being more
potent. Another feature that we probed was the probability of unearthing hydrophilic
interactions around the linker domain that could be targeted. In view of this strategy, we
introduced a 1-propoxypropane linker containing 5 intervening atoms. This, however,
confirmed the lack of any hydrogen bond like interactions with the linker domain,
illustrated by the lack of potency of 15S (IC50 = 401 µM). Surprisingly, a flexible
aliphatic saturated linker was the one preferred. The result suggests that an extended
linker probably serves to place the two QAO scaffolds better within two hydrophobic
regions of FXIa. We therefore, then focused on the length of the linker, which was altered
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from (5 to 12) intervening atoms. The general trend seen within this library indicated that
increasing the length produced a consistent improvement in the potency from 34.3 to 6.1
µM. However, as the length was increased the selectivity profile faltered with maximum
selectivity achieved when the length was 9 atoms. Further increase in linker length
produced an increased potency against other enzymes like FXa and trypsin. Thus
indicating the maximum length required to maintain the potency and selectivity.
Table 12. Inhibition of human factor XIa by sulfated QAOs 7S–24Sa

Aromatic linkers
Inhibitor

R

R’

X

n

IC50

ΔY

µM

%

7S

H

3-OSO3-

p-xylene

6

248±2.6b

100.2±3

8S

H

3-OSO3-

m-xylene

5

59.7±1.1

92.4±5

9S

H

4-OSO3-

m-xylene

5

76.3±1.2

95.8±6
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10S

H

3-OSO3-

o-xylene

4

94.3±2.2

92.6±3.6

11S

H

4-OSO3-

o-xylene

4

57.1±1.7

86.7±3.3

Aliphatic linkers
12S

H

3-OSO3-

Trans-1,4-but-2-ene

4

415±10.3

96.2±7.2

13S

H

3-OSO3-

1,5-pentane

5

88.5±1.1

96±2.15

14S

H

4-OSO3-

1,5-pentane

5

49.3±0.8

92.3±2.6

15S

H

3-OSO3-

1-propoxypropane

5

401±22

94.4±15.8

16S

H

3-OSO3-

1,6-hexane

6

53.4±0.9

95.9±4.9

17S

H

4-OSO3-

1,6-hexane

6

34.3±1.9

87±2.6

18S

-OCH3

4-OSO3-

1,6-hexane

6

34.8±0.8

95.1±2.5

19S

H

4-OSO3-

1,7-heptane

7

23±0.84

96.4±4

20S

H

4-OSO3-

1,8-octane

8

19.6±0.5

80.9±2.4

21S

H

4-OSO3-

1,9-nonane

9

8.2±0.5

101±7.8

22S

H

4-OSO3-

1,10-decane

10

16.6±0.3

94.5±2

23S

H

4-OSO3-

1,11-undecane

11

14.5±0.8

96±5.8

24S

H

4-OSO3-

1,12-dodecane

12

6.1±0.4

90.3±5

a

The IC50, HS and Y values were obtained following nonlinear regression analysis of
direct inhibition of factor XIa. Inhibition was monitored by spectrophotometric
measurements of residual proteases activity (see Experimental section). bErrors represent
±1 SE.
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5.2.3. Inhibition Potency of Sulfated QAOs in Human Plasma.
To assess whether the chromogenic substrate-based inhibition of human factor XIa by
sulfated QAOs translates into activity against macromolecular substrates, we studied
anticoagulant activity in human plasma. The activated partial thromboplastin time
(APTT) assays is typically utilized to identify an inhibitor’s ability to retard the intrinsic
pathway. For the compounds tested (19S-24S) the dose dependent prolongation of about
15 to 20–fold less active in comparison to the potency in buffer was detected. This is
typical of many anticoagulants and could be attributed to interactions with serum
albumin.
Table 13: Effect of Sulfated QAOs on human plasma clotting times.a
Inhibitor

2 x APTT
µM

19S

824

20S

684

21S

813

22S

963

23S

793

24S

891

a

Prolongation of clotting time as a function of concentration of sulfated quinazolinones
for the activated partial thromboplastin time assay (APTT). Clotting assays were
performed in triplicates (SE ≤ 10%) as described in the experimental section.
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5.2.4. Mechanism of Inhibition of Sulfated QAOs.
These molecules were designed to function allosterically and therefore these should
possess inherent non-competitive or uncompetitive mechanism of inhibition. To assess
this, the kinetics of chromogenic substrate S2366 hydrolysis by factor XIa in the presence
of 21S was studied. The plot of the initial rate as a function of Spectrozyme FXIa
concentration displayed a characteristic hyperbolic profile (Figure 38), which was fitted
using the standard Michaelis–Menten equation to derive the KM and Vmax of factor XIa
activity. The KM for Spectrozyme FXIa was found to be 0.27±0.01 mM, which did not
change much as the concentration of 21S increased to 200 µM (0.26±0.32 mM) (Table
14). In contrast, the Vmax decreased from 36.9±1.5 to 9.7±0.37 mAU/min as the
concentration of 21S increased from 0 to 200 µM (Figure 38) (Table 14). Thus, while the
affinity of the small chromogenic substrate remains unaffected by 21S binding, the
proteolytic activity decreases. This is characteristic of a noncompetitive mechanism of
factor XIa inhibition, and most H/HS mimetics230 reported in the literature to date, and
more importantly our previous set of QAOs have exhibited a similar mechanism.206
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Table 14. Michaelis-Menten Kinetics of S2366 hydrolysis by human factor XIa in
the presence of sulfated QAOs.
[21]

Vmax

KM

µM

mAU/min

mM

0

36.9a±0.6

0.23a±0.01

10

36±1.5

0.28±0.04

20

32.1±2

0.31±0.06

50

21±0.7

0.26±0.03

120

17.2±0.6

0.28±0.03

200

9.7±0.4

0.26±0.03

a

Calculated from the rate of hydrolysis at various substrate concentrations measured
spectrophotometrically in 50 mM Tris-HCl buffer, pH 7.4 containing 150 mM NaCl and
0.1% PEG 8000 at 37° C. The Vmax and KM were obtained by nonlinear regression fit of
the data by eq 7 Error = ± SE.
Abs@405 (mAU/min

35

0 uM

30

10uM

25

20uM

20

50uM

15

120 uM

10

200 uM

5
0
0

0.5

1

1.5

2

2.5

[Spectrozyme FXIa] (mM)

Figure 38. Michaelis-Menten kinetics of S2366 hydrolysis by human factor XIa in the
presence of sulfated QAO 21S. The initial rate of hydrolysis at various substrate
concentrations was measured spectrophotometrically in pH 7.4 buffer at 37°C. Solid lines
represent nonlinear regressional fits to the data by the standard Michaelis-Menten
equation to yield KM and Vmax.
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5.2.5. Affinity Studies.
The fluorescence of FXIa–DEGR was monitored as a function of sulfated QAO
concentration. Figure 39 shows the profiles of the titrations for the most potent sulfated
QAOs 19S–24S. The profiles reveal a characteristic sigmoidal dependence on the
concentration of sulfated QAO. This confirms the cooperative binding process observed
in the first generation agents. The profile can be fitted well by the standard, three
parameter Hill equation (eq 8), which gives the maximal fluorescence change (ΔFmax),
the Hill coefficient (n), and the apparent dissociation constant (KD) of binding (Table 15).
By using this equation, the three sulfated QAOs were found to bind with an affinity of
~20 µM, which compare favorably with IC50 measured above (Table 12). The Hill
coefficients were calculated to be in the range of (3.6–5), through which the
fluorescence-based study demonstrates that sulfated QAOs bind to FXIa through a
classic, allosteric interaction process.
Table 15. Binding of Sulfated QAOs to human FXIa a
Inhibitor

ΔFmax

n

%

KD
µM

19S

130±2

3.6±0.56

20±0.8

20S

87.1±1.4

4.3±0.5

20.2±0.7

21S

265±3.1

5.0±0.4

19.9±0.5

Titrations were performed by adding aliquots of a solution of sulfated QAOs (19S–21S)
to 250nM FXIa–DEGR in 50mM Tris–HCl buffer of pH 7.4 containing 150mM NaCl
and 0.1% PEG8000 at 37°C and monitoring the change in fluorescence of FXIa–DEGR
at 547nm (λex = 345nm). The ΔFmax, the Hill coefficient “n”, and KD were obtained by
nonlinear regressional fit of the data by eq 8 Error = ± SE.
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Figure 39. Fractional change in fluorescence of FXIa-DEGR at 547nm (λex = 345nm) as
a function of the concentration of sulfated QAOs (19S–21S). These were recorded in
50mM Tris–HCl buffer of pH 7.4 containing 150mM NaCl and 0.1% PEG8000 at 37°C.
Solid lines represents nonlinear regressional fit to the data using the standard Hill eq 8 to
obtain the ΔFmax, Hill coefficient “n”, and KD of binding.
5.2.6. Analytical Ultracentrifugation of FXIa and FXIa-21S Complex.
Analytical ultracentrifugation (AUC) was performed to observe the oligomerization
properties of FXIa and the effect of the QAO (21S) on the oligomerization. In general
FXIa is predominantly observed as a dimer (s = 6.6S), whereas miniscule amounts of
monomer-dimer equilibrium peak (s = 4.9S, ~13%) were also observed for the
apoenzyme. The FXIa-21S complex also exhibits the presence of a dimer (s = 6.5S)
however, results in an increased detection of monomer-dimer equilibrium (s = ~4.6S,
~19%). This indicates that the QAOs could be targeting FXIa with a unique mechanism
that suggestively destabilizes the FXIa dimer. Literature reports indicate a covalent
disulfide bond between the two monomers100. Additionally, non-covalent interactions
help stabilize the functional dimer form of FXIa.120 The presence of the equilibrium state
is suggestive of 21S interfering with these non-covalent interactions destabilizing the
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stable dimeric form of fXIa.
2

FXIa

1.5
Cs

FXIa-21S

1
0.5
0
0

2

4

6

8

10

12

Sedimentation coefficient

Figure 40. Sedimentation velocity profile showing molecular species of FXIa−ligand
complex. C(s) is the relative concentration of each species: black for unliganded fXIa,
red for the fXIa-21S complex.
5.3. Experimental Procedures
5.3.1. Chemicals, Reagents and Analytical Chemistry
Anhydrous CH2Cl2, THF, CH3CN, DMF, DMA and acetone were purchased from
Sigma-Aldrich (Milwaukee, WI) or Fisher (Pittsburgh, PA) and used as such. Other
solvents used were of reagent gradient and used unmodified. Analytical TLC was
performed using UNIPLATETM silica gel GHLF 250 µm pre-coated plates
(ANALTECH, Newark, DE). Column chromatography was performed using silica gel
(200-400 mesh, 60 Å) from Sigma-Aldrich. Chemical reactions sensitive to air or
moisture were carried out under nitrogen atmosphere in oven-dried glassware. Reagent
solutions, unless otherwise noted, were handled under a nitrogen atmosphere using
syringe techniques. Flash chromatography was performed using Teledyne ISCO
(Lincoln, NE) Combiflash RF system and disposable normal silica cartridges of 30–50 µ
particle size, 230–400 mesh size and 60 Å pore size. The flow rate of the mobile phase
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was in the range of 18 to 35 ml/min and mobile phase gradients of ethyl acetate/hexanes
and CH2Cl2/CH3OH were used to elute compounds.
5.3.2. Proteins and Chromogenic Substrates
Human plasma proteases including thrombin, factor Xa, factor IXa, and factor XIa were
obtained from Haematologic Technologies (Essex Junction, VT). Active sited labeled
FXIa, i.e., FXIa-DEGR, was obtained from US Biological (Marblehead, MA). Bovine αchymotrypsin and bovine trypsin were obtained from Sigma-Aldrich (St. Louis, MO).
Stock solutions of factor XIa, thrombin, trypsin, and chymotrypsin were prepared in 50
mM Tris-HCl buffer, pH 7.4, containing 150 mM NaCl, 0.1% PEG8000, and 0.02%
Tween80. Stock solutions of factor Xa was prepared in 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG8000, and 0.02% Tween80.
Chromogenic

substrates,

Spectrozyme

TH

(H-D-hexahydrotyrosol-Ala-Arg-p-

nitroanilide), Spectrozyme factor Xa (Methoxycarbonyl-D-cyclohexylglycyl-Gly-Arg-pnitroanilide), and Spectrozyme CTY were obtained from American Diagnostica
(Greenwich, CT). Factor XIa chromogenic substrate (S-2366, H-D-Val-Leu-Arg-pnitroanilide.2HCl) and trypsin substrate (S-2222, Benzyl-Ile-Glu(–OH and –OCH3)-GlyArg-p-nitroanilide·HCl) were obtained from Diapharma (West Chester, OH). Pooled
normal human plasma for coagulation assays was purchased from Valley Biomedical
(Winchester, VA). Activated partial thromboplastin time reagent containing ellagic acid,
thromboplastin-D, and 25 mM CaCl2 were obtained from Fisher Diagnostics
(Middletown, VA).
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5.3.3. Chemical Characterization of Compounds
1

H and

13

C NMR were recorded on Bruker-400 MHz spectrometer in either CDCl3,

CD3OD, acetone-d6, DMSO-D6, or D2O. Signals, in part per million (ppm), are either
relative to the internal standard or to the residual peak of the solvent. The NMR data are
reported as chemical shift (ppm), multiplicity of signal (s= singlet, d= doublet, t= triplet,
q= quartet, dd= doublet of doublet, m= multiplet), coupling constants (Hz), and
integration. ESI-MS of compounds were recorded using Waters Acquity TQD MS
spectrometer in positive or negative ion mode. Samples were dissolved in methanol and
infused at a rate of 20 µL/min. The purity of each final compound was greater than 95%
as determined by UPLC-MS.
5.3.4. Synthetic Procedures
General Procedure for Synthesis of Quinazolin-4(3H)-ones
The quinazolinone core structure was synthesized using a condensation reaction between
anthranilamide and suitably substituted benzaldehyde in presence of sodium hydrogen
sulfite and catalytic amounts of p-toluenesulfonic acid. This is a well-established thermal
cyclodehydration reaction.229 To a solution of anthranilamide (1 equiv) in N,Ndimethylacetamide (DMAD) (10mL) 3- or 4-hydroxybenzaldehyde (1 or 2) (1 equiv)
was added followed by the addition of sodium hydrogen sulphate (1.2 equiv) and ptoluenesulfonic acid (0.1equiv) into a single neck flask attached with a condenser and the
mixture was stirred at 150 °C for 3 hrs. The reaction was cooled by the addition of (100
mL) of ice water to form a white precipitate that was filtered off washed with water and a
small amount of methanol and dried in vacuo to obtain a white colored powder.
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Depending on the substitution on the benzaldehyde, two monomers viz. 3a and 3b were
synthesized. The products were formed in 85-90% yields and characterized using NMR.
General Procedure for Protection of Quinazolinone Core Structure
3a and 3b were then acetylated to protect the free hydroxyl group(s). This was done by
solubilizing in dichloromethane followed by addition of N, N-Diisopropylethylamine
DIPEA (2.0 equiv per hydroxyl group) and acetic anhydride (1.0 equiv per hydroxyl
group). This was vigorously stirred at room temperature and after 10 hours extracted
using acidified water and dichloromethane. The organic layer was dried (Na2SO4),
concentrated in vacuo and purified using flash chromatography on silica gel (10-50%
ethyl acetate in hexanes) to give 3a and 3b in 90% yields.
General

Procedure

for

Dimerization

of

Quinazolinone

Monomers

using

Nucleophilic Substitution Reaction
Dimer formation was achieved through a simple substitution reaction. To a solution of 3a
or 3b in N, N-dimethyl formamide was added to potassium carbonate K2CO3 (2.5 equiv)
and stirred for two minutes. This was followed by addition of the respective aryl/alkyl
dibromide (0.5 equiv) followed by vigorous stirring for 12 hours. After the reaction
completed and confirmed by TLC, the reaction mixture was extracted using acidified
water and ethyl acetate. The organic layer was dried over Na2SO4, concentrated in vacuo
and purified using flash chromatography on silica gel (10-50% ethyl acetate in hexanes)
to give the acetylated dimers in 70-80% yield.
General Procedure for the Deprotection of the Acetylated Dimers.
To obtain the hydroxyl dimers, acetylated dimers were solubilized in THF, followed by
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the addition of LiOH.H20 (4 equiv). Vigorous stirring at room temperature for 4-6 hours
afforded the final hydroxyl product. After complete deprotection of acetyl groups
confirmed using TLC, the reaction mixture was extracted using acidified water and ethyl
acetate. The organic layer was separated and dried over Na2SO4, concentrated in vacuo
and purified using flash chromatography on silica gel (20-70% ethyl acetate in hexanes)
to give the deacetylated dimers 7-24 in 70-80% yields.
General Procedure for Synthesis of Sulfated Quinazolin-4(3H)-ones dimers.
Sulfation of phenolic precursors was achieved using microwave assisted chemical sulfation
as described earlier.206,231,232 Briefly, to a stirred solution of polyphenol in anhydrous
CH3CN (1 – 5 mL) at room temperature Et3N (10 equvi per –OH group) and Me3N:SO3
complex (6 equvi per –OH) was added. The reaction vessel was sealed and micro-waved
(CEM Discover, Cary, NC) for 30 min at 90 °C. The reaction mixture was cooled and
transferred to a round bottom flask and volume reduced as much as possible under lowpressure conditions at 25 °C. The reaction mixture was then directly loaded on to a flash
chromatography column and purified using dichloromethane and methanol solvent
system (5-20%) to obtain the sulfated QAOs. The samples were concentrated and reloaded onto a SP Sephadex C-25 column for sodium exchange. Appropriate fractions were
pooled, concentrated in vacuo, and lyophilized to obtain a white powder. Spectral
characteristics of all the sulfated compounds 7S-24S are listed below.
(7S). 1H NMR (DMSOd6, 400MHz): 8.37(s, 2H), 8.3(d, J = 7.7Hz, 2H), 8.22(d, J =
7.96Hz, 2H), 8.01-7.94(m, 4H), 7.7(s, 4H), 7.67-7.63(m, 2H), 7.51-7.4(m, 2H), 7.377.36(m, 2H), 5.83(s, 4H).

13

C NMR (DMSOd6, 100MHz): 165.92, 158.93, 157.57,
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151.25, 138.66, 136.36, 134.3, 129.53, 128.37, 127.6, 127.16, 123.3, 119.06, 117.93,
114.76, 114.55, 67.70. MS (ESI) calculated for C36H24N4Na2O10S2 [(M – Na)]-, m/z
759.71, found [(M – 2Na)]2-, m/z 367.899.
(8S). 1H NMR (DMSOd6, 400MHz): 8.38(s, 2H), 8.29(d, J = 7.8Hz, 2H), 8.18(d, J =
7.9Hz, 2H), 8.02-7.95(m, 5H), 7.68-7.60(m, 4H), 7.53-7.44(m, 3H), 7.37(d, J = 7.56Hz,
2H).

13

C NMR (DMSOd6, 100MHz): 165.99, 158.70, 153.92, 151.23, 138.26, 136.74,

134.31, 128.86, 128.8, 127.66, 127.21, 123.28, 123.04, 120.37, 114.57, 67.89. MS (ESI)
calculated for C36H24N4Na2O10S2 [(M – Na)]-, m/z 759.71, found [(M – 2Na)]2-, m/z
367.931.
(9S). 1H NMR (DMSOd6, 400MHz): 8.5(d, J = 8.65Hz, 4H), 8.14 (d, J = 8.12Hz, 2H),
7.97-7.90(m, 5H), 7.66-7.61(m, 5H), 7.36(d, J = 8.64, 4H), 5.87(s, 4H).

13

C NMR

(DMSOd6, 100MHz): 165.89, 158.80, 156.13, 136.91, 134.23, 131.79, 129.03, 128.75,
127.80, 127.48, 127.32, 126.86, 123.20, 119.81, 114.32, 67.82. MS (ESI) calculated for
C36H24N4Na2O10S2 [(M – Na)]-, m/z 759.71, found [(M – 2Na)]2-, m/z 367.931.
(10S). 1H NMR (DMSOd6, 400MHz): 8.34(s, 2H), 8.17(d, J = 4.6Hz, 2H), 8.0-7.83(m,
6H, (m, 2H), 8.0-7.9(m, 8H), 7.8-7.4(m, 8H), 6.08(s, 4H).

13

C NMR (DMSOd6,

100MHz): 165.8, 158.57, 153.84, 151.11, 138.2, 135.12, 134.1, 130.37, 128.73, 127.5,
126.97,

123.16,

122.96,

120.35,

114.37,

66.64.

MS

(ESI)

calculated

for

C36H24N4Na2O10S2 [(M – Na)]-, m/z 782.71, found [(M – 2Na)]2-, m/z 367.963.
(11S). 1H NMR (DMSOd6, 400MHz): 8.3(d, J = 8.8Hz, 4H), 7.93(d, J = 8Hz, 2H), 7.87.7(m, 6H), 7.43-7.41(m, 2H), 7.32-7.27(m, 2H), 7.21(d, J = 8.8Hz, 4H), 5.98(s, 4H). 13C
NMR (DMSOd6, 100MHz): 165.74, 158.67, 156.05, 151.25, 135.18, 134.07, 131.71,
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130.06, 128.92, 128.60, 127.4, 126.60, 122.91, 119.70, 114.14, 66.6. MS (ESI) calculated
for C36H24N4Na2O10S2 [(M – Na)]-, m/z 782.71, found [(M – 2Na)]2-, m/z 367.889.
(12S). 1H NMR (DMSOd6, 400MHz): 8.35-8.20(m, 6H), 7.9(s, 4H), 7.64(s, 2H), 7.43(m,
5H), 6.5(s, 2H), 5.4(s, 4H). 13C NMR (DMSOd6, 100MHz): 165.8, 153.9, 151.2, 138.3,
134.3, 128.84, 128.5, 127.62, 127.2, 123.2, 123.03, 120.4, 114.52, 66.29, 52.77. MS
(ESI) calculated for C32H22N4Na2O10S2 [(M – Na)]-, m/z 732.65, found [(M – 2Na)]2-, m/z
342.908.
(13S). 1H NMR (DMSOd6, 400MHz): 8.24(s, 2H), 8.17(d, J = 7.68Hz, 2H), 8.06(d, J =
7.64Hz, 2H), 7.91-7.84(m, 4H), 7.53-7.52(m, 2H), 7.38-7.28(m, 4H), 4.72(t, J = 6.3Hz,
4H), 2.04-1.97(m, 4H), 1.8-1.73(m, 2H).

13

C NMR (DMSOd6, 100MHz): 166.3, 158.8,

153.89, 151.13, 138.4, 134.12, 128.79, 127.60, 127.02, 123.18, 122.94, 120.40, 114.62,
66.67, 52.75, 27.94, 22.32, 13.56. MS (ESI) calculated for C33H26N4Na2O10S2 [(M – Na)], m/z 748.69, found [(M – 2Na)]2-, m/z 350.940.
(14S). 1H NMR (DMSOd6, 400MHz): 8.38(d, J = 8.8, 4H), 8.04(d, J = 8.0, 2H), 7.88(m,
4H), 7.51-7.47(m, 2H), 7.27(d, J = 8.8, 4H), 4.71(s, 4H). 13C NMR (DMSOd6, 100MHz):
166.2, 158.90, 156.08, 151.26, 134.04, 131.92, 128.92, 127.45, 126.64, 123.12, 119.8,
66.59, 52.75, 27.95, 22.34. MS (ESI) calculated for C33H26N4Na2O10S2 [(M – Na)]-, m/z
748.69, found [(M – 2Na)]2-, m/z 351.004.
(15S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.76Hz, 4H), 8.02(d, J = 8.12Hz, 4H),
7.92-7.85(m, 4H), 7.47(t, J = 7.96Hz, 2H), 7.33(d, J = 8.73Hz, 4H), 4.89(s, 4H).

13

C

NMR (DMSOd6, 100MHz): 165.8, 153.9, 151.2, 138.3, 134.3, 128.84, 128.5, 127.62,
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127.2, 123.2, 123.03, 120.4, 114.52, 66.29, 52.77. MS (ESI) calculated for
C32H24N4Na2O11S2 [(M – Na)]-, m/z 750.66, found [(M – 2Na)]2-, m/z 351.861.
(16S). 1H NMR (DMSOd6, 400MHz): 8.3(s, 2H), 8.25(d, J = 7.36Hz, 2H), 8.14(d, J =
8Hz, 2H), 7.98-7.93(m, 4H), 7.58-7.37(m, 6H), 4.76(s, 4H), 2.0(s, 4H), 1.7(s, 4H).

13

C

NMR (DMSOd6, 100MHz): 166.29, 158.77, 153.88, 151.11, 138.41, 134.12, 128.81,
127.59, 127.03, 123.189, 122.95, 120.42, 114.6, 66.77, 28.14, 25.4. MS (ESI) calculated
for C34H28N4Na2O10S2 [(M – Na)]-, m/z 739.72, found [(M – 2Na)]2-, m/z 357.915.
(17S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.8, 4H), 8.1(d, J = 7.97Hz, 2H), 7.937.89(m, 4H), 7.56-7.52(m, 2H), 7.34(d, J = 8.8, 4H), 4.74(t, J = 6.32Hz, 4H), 2.0(s, 4H),
1.7(s, 4H).

13

C NMR (DMSOd6, 100MHz): 166.29, 158.77, 153.88, 151.11, 138.41,

134.12, 128.81, 127.59, 127.03, 123.189, 122.95, 120.42, 114.6, 66.77, 28.14, 25.4. MS
(ESI) calculated for C33H26N4Na2O10S2 [(M – Na)]-, m/z 762.72, found [(M – 2Na)]2-, m/z
357.947.
(18S). 1H NMR (DMSOd6, 400MHz): 8.40(d, J = 8.6Hz, 4H), 7.8(d, J = 9.1Hz, 2H),
7.51-7.48(m, 2H), 7.33-7.31(m, 6H), 4.73(t, J = 6.4Hz), 3.8(s, 6H), 2.0(s, 4H), 1.7(s, 4H)
13

C NMR (DMSOd6, 100MHz): 165.30, 157.34, 156.86, 146.78, 132.13, 129.13, 128.5,

125.4, 119.8, 114.93, 101.39, 66.55, 55.48, 28.11, 25.34. MS (ESI) calculated for
C36H32N4Na2O10S2 [(M – Na)]-, m/z 822.77, found [(M – 2Na)]2-, m/z 387.962.
(19S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.7Hz, 4H), 8.06(d, J = 8.16Hz, 2H),
7.85-7.81(m, 4H), 7.53-7.5(m, 2H), 7.3(d, J = 8.7Hz, 4H), 4.65(t, J = 6.4Hz, 4H), 3.0(s,
4H), 1.16(s, 1H), 1.08-1.0(m, 6H).

13

C NMR (DMSOd6, 100MHz): 166.2, 158.88,

156.07, 151.25, 134.04, 131.92, 128.92, 127.44, 126.68, 123.18, 119.81, 114.39, 66.73,
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52.75, 28.58, 28.16, 25.57. MS (ESI) calculated for C35H30N4Na2O10S2 [(M – Na)]-, m/z
776.74, found [(M – 2Na)]2-, m/z 364.987.
(20S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.8Hz, 4H), 8.13(d, J = 7.93Hz, 2H),
7.94-7.88(m, 4H), 7.61-7.54(m, 2H), 7.34(d, J = 8.8Hz, 4H), 4.71(t, J = 6.4Hz, 4H), 2.091.89(m, 4H), 1.56-1.47(m, 4H), 1.08(t, J = 7.2Hz, 4H). 13C NMR (DMSOd6, 100MHz):
166.19, 158.89, 156.09, 151.25, 134.02, 131.91, 128.91, 127.44, 126.65, 123.16, 119.80,
114.39, 66.72, 52.75, 28.69, 28.16, 25.52. MS (ESI) calculated for C36H32N4Na2O10S2
[(M – Na)]-, m/z 790.77, found [(M – 2Na)]2-, m/z 371.962.
(21S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.8Hz, 4H), 8.13(d, J = 8.24Hz, 2H),
7.95-7.89(m, 4H), 7.62-7.58(m, 2H), 7.34(d, J = 8.8Hz, 4H), 4.71(t, J = 6.4Hz, 4H), 2.11.87(m, 4H), 1.54(s, 4H), 1.4(s, 6H).

13

C NMR (DMSOd6, 100MHz): 166.22, 158.89,

156.13, 151.15, 134.05, 131.83, 129.9, 128.93, 127.37, 126.68, 123.19, 119.80, 115.30,
114.39, 66.76, 52.74, 28.86, 28.70, 28.64, 28.17, 25.55. MS (ESI) calculated for
C37H34N4Na2O10S2 [(M – Na)]-, m/z 804.80, found [(M – 2Na)]2-, m/z 379.034.
(22S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.8Hz, 4H), 8.14(d, J = 8.3Hz, 2H),
7.96-7.90(m, 4H), 7.63-7.60(m, 2H), 7.4(d, J = 8.8Hz, 4H), 4.71(t, 6.52Hz, 4H), 1.931.86(m, 4H), 1.54-1.49(m, 4H), 1.4-1.34(m, 8H).

13

C NMR (DMSOd6, 100MHz):

166.22, 159.1, 134.16, 130.03, 128.99, 126.71, 126.50, 123.21, 119.80, 115.36, 114.17,
66.81, 28.77, 28.61, 28.10, 25.44. MS (ESI) calculated for C38H36N4Na2O10S2 [(M – Na)], m/z 818.82, found [(M – 2Na)]2-, m/z 386.042.
(23S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.8Hz, 4H), 8.13(d, J = 8.0Hz, 2H),
7.94-7.88(m, 4H), 7.6(t, J = 1.6, 2H), 7.34(d, J = 8.8Hz, 4H), 4.7(t, J = 6.4Hz, 4H), 1.93140

1.87(m, 4H), 1.53-1.48(m, 4H), 1.38-1.31(m, 10H).

13

C NMR (DMSOd6, 100MHz):

166.19, 158.89, 156.09, 151.26, 134.02, 131.90, 128.90, 127.45, 126.64, 123.16, 119.79,
114.39, 66.72, 28.89, 28.85, 28.71, 28.55, 28.33, 28.15, 25.53. MS (ESI) calculated for
C39H38N4Na2O10S2 [(M – Na)]-, m/z 832.85, found [(M – 2Na)]2-, m/z 392.986.
(24S). 1H NMR (DMSOd6, 400MHz): 8.4(d, J = 8.8Hz, 4H), 8.14(d, J = 8.0Hz, 2H),
7.97-7.91(m, 4H), 7.64-7.60(m, 2H), 7.35(d, J = 8.8Hz, 4H), 4.71(t, J = 6.5Hz, 4H), 1.911.88(m, 4H), 1.53-1.49(m, 4H), 1.37-1.23(m, 12H).

13

C NMR (DMSOd6, 100MHz):

166.29, 159.08, 158.87, 134.20, 130.06, 128.99, 126.45, 123.22, 119.80, 115.36, 114.35,
114.15, 66.78, 28.60, 28.08, 25.42. MS (ESI) calculated for C40H40N4Na2O10S2 [(M –
Na)]-, m/z 846.88, found [(M – 2Na)]2-, m/z 399.962.
5.3.5. Direct Inhibition of Factor XIa by Sulfated QAOs.
A chromogenic substrate hydrolysis assay using a microplate reader (FlexStation III,
Molecular Devices) was used to measure direct inhibition of FXIa, as described
earlier.206,233 Generally, each well of the 96-well microplate had 85 µL of pH 7.4 buffer
(50 mM TrisHCl, 150 mM NaCl, 0.1% PEG8000, and 0.02% Tween80) to which 5 µL of
a potential FXIa inhibitor (or solvent reference) was added followed by 5 µL of FXIa to
give 0.765 nM in the well. After 10 min incubation at 37 °C, 5 µL FXIa substrate S2366
(345 µM in the well) was rapidly added and the residual FXIa activity was measured
from the initial rate of increase in absorbance at 405 nm. Stocks of FXIa inhibitors were
20 mM, which were then serially diluted to give twelve different aliquots in the plate
wells. Relative residual FXIa activity at each concentration of the inhibitor was
calculated from the ratio of FXIa activity in the presence and absence of the inhibitor. Eq
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6 was used to fit the dose–dependence of residual proteinases activity to obtain the
potency (IC50) and efficacy (∆Y) of inhibition. In this equation, Y is the ratio of residual
factor XIa activity in the presence of inhibitor to that in its absence (fractional residual
activity), YM and Y0 are the maximum and minimum possible values of the fractional
residual proteinase activity, IC50 is the concentration of the inhibitor that results in 50%
inhibition of enzyme activity, and HS is the Hill slope. Nonlinear curve fitting resulted in
YM, Y0, IC50 and HS values.
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5.3.6. Inhibition of Proteases of the Coagulation and Digestive Systems.
The inhibition potential of 500 µM of 7S to 24S against coagulation enzymes including
thrombin, factor IXa and factor Xa and digestive enzymes including trypsin and
chymotrypsin was evaluated using chromogenic substrate hydrolysis assays reported in
the literature. These assays were performed using substrates appropriate for the enzyme
being studied under conditions closest to the physiological condition (37 °C and pH 7.4),
except for thrombin, which was performed at 25 ºC and pH 7.4. The concentrations of
enzymes and substrates in microplate wells, respectively, were: 6 nM and 50 mM for
thrombin; 1.09 nM and 125 mM for factor Xa, 2.5 ng/ml and 80 mM for bovine trypsin;
and 500 ng/ml and 240 mM for bovine chymotrypsin and 89 nM and 425 mM for FIXa.
The ratio of the proteolytic activity of an enzyme in the presence of the sulfated QAO to
that in its absence was used to calculate percent inhibition (%).
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5.3.7. Michaelis–Menten Kinetics of Substrate Hydrolysis in Presence of 21S.
The initial rate of S2366 hydrolysis by FXIa was obtained from the linear increase in
absorbance at 405 nM corresponding to less than 10% consumption of S2366. The initial
rate was measured as a function of various concentrations of the substrate (0.03–2 mM)
in the presence of fixed concentration of 21S in 50 mM TrisHCl buffer, pH 7.4,
containing 150 mM NaCl, 0.1% PEG8000, and 0.02% Tween80 at 37 OC. The data was
fitted using the standard Michaelis–Menten eq 7 to determine the KM and VMAX.
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5.3.8. Equilibrium dissociation constant (KD) of Sulfated QAOs Binding to Human
Factor XIa.
Fluorescence experiments were performed using a QM4 spectrofluorometer (Photon
Technology International, Birmingham, NJ) in 50 mM Tris-HCl buffer of pH 7.4
containing 150 mM NaCl and 0.1% PEG8000 at 37 °C. The equilibrium dissociation
constant (KD) of sulfated QAOs – FXIa complex was measured using the change in the
fluorescence of the active site dansyl group due to binding. Titrations were performed by
adding aliquots of a solution of sulfated QAOs (19S, 20S and 21S) in the above buffer to
a fixed concentration of FXIa–DEGR (250 nM) and monitoring the change in the
fluorescence of FXIa-DEGR at 547 nm (λEX = 345 nm). The slit widths on the excitation
and emission side were 1mm each. The change in fluorescence at 547 nm was fitted using
the standard Hill equation for ligand binding eq 8 for co-operative binding to obtain the
apparent dissociation constant (KD,app) of binding. In this equation, ΔF represents the
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change in fluorescence following addition of sulfated QAO from the initial fluorescence
(F0), while ΔFMAX represents the maximal change in fluorescence. Hill coefficient ‘n’ is a
measure of the cooperativity of binding.
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5.3.9. Activated Partial ThromboplastinTime (APTT)
Intrinsic clotting time was measured in a standard one–stage recalcification assay with a
BBL Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD). For the aPTT assay, x µL
of same molecules was mixed with (100-x) µL of citrated human plasma and 100 µL of
prewarmed APTT reagent (0.2% ellagic acid). After incubation for 4 min at 37 OC,
clotting was initiated by adding 100 µL of pre-warmed 25 mM CaCl2 and time to clot
noted. The data were fit to a quadratic trend line, which was used to determine the
concentration of the inhibitor necessary to double the clotting time. Clotting time in the
absence of an anticoagulant was determined in similar fashion using 10 µL of deionized
water and/or appropriate organic vehicle and was found to be 34.8 s for APT.
5.3.10. Analytical Ultracentrifugation of FXIa and FXIa-21S complex.
FXIa-DEGR was diluted to 0.2 mg/mL in 50 mM Tris-HCl buffer of pH 7.4 containing
150 mM NaCl and 0.1% PEG8000 at 20 °C. Samples (420 µL) of FXIa alone and FXIa
with 100 µM 21S, with a buffer sample were run at 25000 rpm overnight at 20° C in a
Beckman Coulter Proteome Lab XL-I analytical ultracentrifuge. Absorbance (λ = 345nm)
and interference scans were recorded until the boundary moved to the bottom of the cell.
The continuous distribution c(S) distribution analysis was performed using SEDFIT
(https://sedfitsedphat.nibib.nih.gov).
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CHAPTER 6: SIGNIFICANCE OF CURRENT WORK AND FUTURE
DIRECTIONS
6.1. Novel Hexasaccharide Based Activators of Heparin co-factor II and
Antithrombin
Antithrombin activation has been the primary indirect mechanism of
anticoagulation by heparin and its analogs. Structural studies, however, have revealed the
specificity of interaction involved in this mechanism, shedding light on the fact that a
similar system could exist for related serpins like HCII. Reports did suggest the lack of
specificity in the HCII system primarily due to the lack of structural homogeneity in the
sequences known to activate it and to the lack of any structural knowledge. The
utilization of computational resources to solve this difficult puzzle could offer an
alternative. The computational techniques we utilized did predict highly specific
structures for both the HCII and the AT system. This lays the foundation for utilization of
similar techniques on other unknown protein-GAG systems to predictively identify
sequences. HX1 was identified as one of the first heparin based hexasaccharide
sequences to potently target both AT and HCII. This property has the added advantage
that this sequence is capable of targeting both venous and arterial thrombosis. Targeting
HCII introduces the capability of inhibiting both free and bound thrombin.
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HX1

A major problem with heparin-based
anticoagulants has been the occurrence of
thrombocytopenia and bleeding complications.
The

problem

of

heparin-induced

thrombocytopenia was diminished through the
utilization of the smaller and homogeneous
heparin pentasaccaharide; the hexasaccharide

Antithrombin crystals

thus synthesized could also be postulated to possess a similar advantage. Other bleeding
complication are generally attributed to the potent affinity of heparin pentasaccharide,
however the moderate affinity observed with the hexasaccharide without the loss of
activation potential could reduce the bleeding complications observed with simple
measures like dialysis or the utilization of an antidote.
The study thus performed is an initial step toward further understanding the
complex HCII system. However, the utilization of our computational approach could
have implications for this system. Experimental data brings to light the structural aspect
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of these hexasaccharides. However, mechanistic understanding needs to be clarified.
Some of the mechanistic studies that we are already in the process of undertaking include
the salt dependent studies to recognize ionic component of the interaction of these
sequences with HCII and AT. Structural elucidation through the utilization of X-ray
crystallography could serve as important tool to gain a more comprehensive
understanding. These have already been undertaken with numerous AT crystals being
soaked with the potent HX1. However, efforts to obtain the structure and the site of
binding have failed. Similarly, the promise these offer warrants animal studies, which we
plan to undertake through the help of our collaborators.
6.2. Differential Recognition of Coagulation Proteins by a Heparan sulfate
containing 2-O-sulfated Glucuronic acid
GAGs are highly heterogeneous structures decorated by an array of sulfates
(!OSO3¯), the placement of which induces recognition and modulation of proteins that
possess surfaces draped with positively charged Arg/Lys residues. The interaction
patterns involved dictate the type of function modulated which range from physiological
modulation of growth to pathophysiological ones like cancer and microbial invasion. The
emphasis is on the structure of the GAG interacting with the protein.
Our work involves recognizing such a rare sequence in the form of HS2S2S, which
was found to be unique in many ways. Its natural occurrence and the possibility of it
being used to unearth newer interaction profiles caught our attention. Our experimental
findings suggest a novel profile with it targeting usual serpins like AT and HCII.
However, the direct inhibition of thrombin is a feature not generally seen in heparin147

based polymers. Further, the correlation of these results with our computational
predictions suggests the importance of studying such rare sequences through the use of a
more predictable model.
Our study lays the foundation for similar studies to be performed to unearth novel
interactions of GAGs with the variety of proteins these are known to interact. The
computational resources we utilized thus offer an avenue to predictively study such
systems.
6.3. Sulfated Quinazolin-4(3H)-ones as Allosteric Modulators Targeting FXIa
Numerous studies have signified the benefits of directly targeting upstream coagulation
proteases like FXIa. Targeting FXIa does not produce any bleeding complications,
subsequently without altering the normal hemostasis. Additionally, the lack of FXIa does
not produce significant problems in individual carriers of the mutation with it. Animal
studies have revealed similar trends with no complications observed. Altogether these
features make it a potentially attractive target.
The dual element strategy, was successfully
incorporated to develop the initial QAOs206, and
similarly used to design allosteric inhibitor for
thrombin.177 These initial QAOs were the first group
of allosteric inhibitors of FXIa. Sulfated pentagalloyl
glucoside are the other structurally diverse allosteric

21S

inhibitors of FXIa, which were reportedly found to function by a different allosteric
mechanism. The present study extends our structural and mechanistic understanding of
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the QAOs based inhibitors. The second generation of compounds has stretched the
potency by 9-fold (21S) while maintaining a similar selectivity profile. This generation
primarily focused on the linker domain, thus unearthing important features required in
this domain especially in terms of its geometry and length, additionally the positioning of
the sulfate group has also been deciphered. Mechanistically, the analytical
ultracentrifugation studies have thrown light into the interference with the non-covalent
dimer forming interactions as a possible route of inhibition, further confirming a noncompetitive mechanism of action. This study validates on the utilization of the dual
element strategy and its extension to gain a reasonable structure-activity understanding of
the binding site in addition to the mechanistic knowledge gained.
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APPENDIX A
Naming convention for the H/HS monosaccharides and the 36 disaccharide building
blocks derived from them.
Namea
Name
Conf.b Anomer
Disaccharide Building Blocks
1
ua2Aua2AuaA
IdoAp
C4
αZbB-YbCA
1
YbC6A
YbH36A
ZbBuc2Auc2Aua2A
IdoAp2S
C4
α2
YbC6A
YbC6A
YbH36A
ucA
IdoAp
SO
αZbB-Yb2A
uaA-Yb2A
ucA-Yb2A
2
Zb2Bua2Auc2Auc2A
IdoAp2S
SO
α4
Yb2A
Yb2A
Yb23A
ZbBuc2AYb2A
GlcNp2S
C1
α4
Yb26A
Yb2A
Zb2BuaAYb23A
GlcNp2S3S
C1
αYb26A
Yb26A
4
ZbBucAYb26A
GlcNp2S6S
C1
αYb23A
Yb26A
4
Zb2Bua2AYb236A GlcNp2S3S6S
C1
α4
Yb23A
Yb26A
ZbBuc2AYb26A
GlcNp2S6S
C1
α4
Yb236A
Yb26A
uaAYbCA
GlcNp2Ac
C1
αZbB-YbHA
4
Yb23A
ucAYbC6A GlcNp2Ac6S
C1
αuaA-YbCA
4
Yb23A
ua2AYbHA
GlcNp
C1
αucA-YbCA
4
Yb23A
ua2AuaAYbH3A GlcNp3S
C1
α4
YbCA
Yb236A
uc2AucAYbH36A GlcNp3S6S
C1
α4
YbCA
Yb236A
uaAua2AZbB
GlcAp
C1
β4
YbC6A
YbH3A
ucAuc2AZb2B
GlcAp2S
C1
βa
YbC6A
YbH3A
Symbols: Z = D-GlcAp, u = L-IdoAp, Y = D-GlcNp. Ring conformations: a = 1C4; b =
4
C1; c = 2SO. Substituents: H = No substitution at position 2; Ac = N-acetyl, S = sulfate;
Anomer configuration: A = α, B = β. bConformation.
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APPENDIX B
Average torsion across the 1→4 inter-glycosidic bonds used in this CVLS study.

Disaccharide Building Block

Φ
(O5-C1-O1-C4’)

Ψ
(C1-O1-C4’-C5’)

GlcAp(1!4)GlcNp
IdoAp(1!4)GlcNp

-81.8
-87.7

-114.0
-128.3

GlcNp(1!4)GlcAp
GlcNp(1!4)IdoAp

91.1
87.4

-151.6
-132.3
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